Over a month ago
Recommendations
BTIG analyst Justin Zelin…
BTIG analyst Justin Zelin names Immunocore (IMCR) as his BTIG Top Pick for first half of 2023, replacing Adicet Bio (ACET) on that list. The company has surprised observers of the field of TCR therapy with multiple corporate updates in 2022, led primarily by approval of lead asset KIMMTRAK, or tebentafusp, in January 2022 which was followed by strong revenue growth and distribution across international regions, the analyst tells investors in a research note. Zelin has a Buy rating and a $85 price target on the stock.
Show Hide Related Items >> <<
12/08/22 Immunocore presents ovarian cancer expansion data for IMC-C103C 12/02/22 Immunocore, Gadeta announce agreement to develop gamma delta TCR ImmTAC 11/11/22 Immunocore presents new biomarker analysis for KIMMTRAK 11/09/22 Medison Pharma announces expansion of agreement with Immunocore 12/11/22 Adicet Bio reports data from ongoing ADI-001 Phase 1 trial 11/29/22 Adicet Bio appoints Nancy Boman, M.D Chief Regulatory Officer 10/17/22 RA Capital Management reports 5.5% passive stake in Adicet Bio 12/12/22 H.C. Wainwright Adicet Bio price target raised to $38 from $34 at H.C. Wainwright 09/21/22 JPMorgan Adicet Bio initiated with Overweight, $23 target at JPMorgan 09/21/22 JPMorgan Adicet Bio initiated with an Overweight at JPMorgan 03/30/22 SMBC Nikko Adicet Bio initiated with an Outperform at SMBC Nikko 12/15/22 Goldman Sachs Immunocore upgraded to Buy from Neutral at Goldman Sachs 11/30/22 Barclays Immunocore initiated with an Overweight at Barclays 11/21/22 H.C. Wainwright Immunocore price target raised to $90 from $80 at H.C. Wainwright 09/14/22 JPMorgan Immunocore price target raised to $67 from $60 at JPMorgan 11/09/22 Immunocore reports Q3 EPS GBP0.13 vs. (GBP0.69) last year 08/10/22 Immunocore reports Q2 EPS EUR 0.14 vs EUR 0.75 last year 11/08/22 Adicet Bio reports Q3 EPS (53c), consensus (53c) 08/10/22 Adicet Bio reports Q2 EPS (56c), consensus (45c) 12/12/22 What You Missed On Wall Street On Monday 12/12/22 What You Missed On Wall Street This Morning
On The Fly
Get caught up quickly on…
Show Hide Related Items >> <<
12/12/22 Weber rises 23.3% 12/12/22 Weber rises 23.3% 12/12/22 Weber rises 23.1% 12/12/22 Weber to be taken private by BDT Capital in $8.05 per share transaction WBA Walgreens Boots Alliance 12/08/22 Walgreens Boots Alliance sells $1.0B in AmerisourceBergen shares 12/08/22 Walgreens Boots Alliance launches free Paxlovid delivery with DoorDash, Uber 12/06/22 Walmart to pay $500,000 over workers' compensation prescription procedures 11/08/22 VMware, Equinix announce expanded global relationship 11/08/22 HP Enterprise, VMware announce next phase of partnership 11/08/22 Wipro, VMware extend collaboration with dedicated business unit 10/17/22 VMware, First Nations University of Canada launch digital partnership 12/12/22 Universal Technical falls -16.3% 12/12/22 Universal Technical falls -10.6% 12/12/22 Universal Technical trading resumes 12/12/22 Universal Technical trading halted, volatility trading pause 11/18/22 Adtalem Global Education appoints Blake Simpson as CCO 10/05/22 Under Armour announces executive leadership changes 08/03/22 Under Armour sees 'overabundance' of product hitting the market in 2022 08/03/22 Under Armour's Plank says Browne in running for permanent CEO job 12/04/22 Fly Intel: Top five weekend stock stories 09/09/22 Tapestry announces long-term financial targets 08/04/22 Tapestry COO Tom Glaser retires, Scott Roe to succeed 11/09/22 Cinedigm reaches new distribution agreement with Samsung 11/03/22 ironSource announces expansion of partnership with Samsung 10/31/22 Rambus and Samsung extend comprehensive pact for additional 10 years 10/20/22 Verizon starts orders for Samsung Galaxy XCover6 Pro 12/12/22 Rivian Automotive pauses plans to produce electric commercial vans in Europe 12/06/22 Vietnam-based EV maker VinFast plans for U.S. IPO 12/05/22 Rivian Automotive enters wind energy deal with Apex Clean Energy 11/14/22 Soros Fund Management buys Sierra Wireless, exits Kinder Morgan in Q3 $253.52 / -20.82 (-7.59%)
12/08/22 RH says Q3 gross margin contracted 50bps 12/08/22 RH to acquire Dmitriy & Co 12/08/22 RH CEO to exercise expiring options 11/14/22 Berkshire Hathaway adds TSMC, exits STORE Capital in Q3 11/02/22 Qualcomm falls 7% to $104.90 after Q1 guidance misses estimates 11/02/22 Qualcomm sees low-double digits handset volume declines for 2022 10/25/22 Cognizant expands collaboration with Qualcomm 09/30/22 L&T Technology Services, Qualcomm collaborate to deploy end-to-end 5G solutions 11/21/22 Pitney Bowes confirms 'ongoing dialogue with Hestia Capital over many months' 11/21/22 Activist Hestia wants Pitney Bowes to review capital and strategy, Reuters says 11/21/22 Hestia Capital reports 6.9% stake in Pitney Bowes, engaging in talks 11/18/22 Pitney Bowes announces 6.5% general rate increase for e-commerce services 11/18/22 Pembina Pipeline announces settlement agreement with Ruby Pipeline 10/18/22 TC Energy, Pembina Pipeline enter into carbon sequestration evaluation agreement 08/25/22 Pembina Pipeline appoints Cameron Goldade as CFO 08/15/22 Pembina Pipeline completes transaction with KKR to create PGI 12/06/22 Micron ships Micron 2550 NVMe SSD to global PC OEM customers 11/29/22 Micron CFO says pricing has trended 'well below' expectations 11/16/22 Micron down 5% after warning outlook for 2023 has weakened 11/16/22 Micron announces further actions to address market conditions 12/12/22 Thomson Reuters, Blackstone to sell shares of LSEG to Microsoft 12/12/22 Microsoft to buy 4% stake in LSEG amid 10-year cloud partnership 12/09/22 Amazon, Bandai Namco partner over release of 'Blue Protocol' in 2023 11/08/22 Levi Strauss appoints Michelle Gass as President, to succeed Bergh as CEO 10/07/22 Levi Strauss falls -7.4% 10/06/22 Levi Strauss falls 3% to $15.40 after Q3 earnings, FY22 guidance cut 07/28/22 Kohl's becomes 'exclusive' wholesale retailer for Levi's SilverTab collection 12/12/22 Karyopharm announces updated results from Phase 1 selinexor data 11/03/22 Karyopharm to present new selinexor data in myelofibrosis and myeloma 11/01/22 Karyopharm, Menarini Group: EC grants orphan designation for selinexor 10/31/22 Karyopharm and Menarini announce EC granted orphan designation for selinexor HZNP Horizon Therapeutics $112.34 / +14.995 (+15.40%)
12/11/22 Sanofi does not intend to make offer for Horizon Therapeutics 11/10/22 GT Biopharma CEO says 'pleased with progress' with TriKE platform 09/12/22 GT Biopharma announces highlights from GTB-5550 study 12/12/22 Whole Earth Brands CEO Albert Manzone steps down 07/28/22 Swerve launches next generation of sugar alternative products 06/21/22 Whole Earth Brands announces global strategic ESG goals for 2030 06/17/22 Whole Earth Brands increases revolving credit facility to $125M 12/12/22 GT Biopharma, Fate present preclinical data on dual antigen targeting approach 12/11/22 Fate presents interim data from dose-escalation stage of Phase 1 study of FT819 12/11/22 Fate presents interim clinical data from ongoing Phase 1 stuty of FT576 11/07/22 Fate announces exercise by ONO of option to FT825/ONO-8250 12/05/22 Dynagas LNG reports new U.S. tax rules on PTPs don't affect unit holders 06/27/22 Dynagas LNG reports Q1 EPS 18c vs. 21c in Q1 last year $103.78 / +2.175 (+2.14%)
12/12/22 CVS, Walgreens in $10.7B opioid settlement with attorneys general 11/21/22 CVS Health board approves 2022 Repurchase Program for $10B of shares 11/20/22 Fly Intel: Top five weekend stock stories 11/16/22 Oak Street Health turns green, up 3% in afternoon trading 12/02/22 Credit Suisse rallies after Chairman says outflows 'basically stopped' 11/23/22 Credit Suisse sees likely loss for Wealth Management in Q4 11/23/22 Credit Suisse sees 'substantial' loss of up to CHF 1.5B in Q4 11/23/22 Credit Suisse confirms capital ratio guidance from October 27 $78.62 / +16.54 (+26.64%)
12/12/22 Coupa Software to be acquired by Thoma Bravo for $81 per share in cash 11/23/22 Coupa Software up 34% after takeover report triggered halt 11/23/22 Coupa Software trading resumes 11/23/22 Coupa halted for volatility after jumping 10% on Bloomberg report 12/02/22 Coinbase says Apple blocked last app release on NFTs 11/30/22 Coinbase Wallet to stop supporting BCH, ETC, XLM, XRP 11/21/22 Crypto names down in pre-market as bitcoin falls to one-week low 11/16/22 Cathie Wood's ARK Investment bought 245.6K shares of Coinbase today 10/19/22 Box renews partnership with Japan's Ministry of the Environment 08/24/22 Box reports Q2 RPOs up 14% y/y at $1.05B 08/18/22 Box announces appointment of Walia to board of directors 06/23/22 Box announces collaboration with Fujifilm Business $276.76 / -1.825 (-0.66%)
12/12/22 Amgen to acquire Horizon Therapeutics for $116.50 per share in cash 12/12/22 Amgen to acquire Horizon Therapeutics for $116.50 per share in cash 12/11/22 Fly Intel: Top five weekend stock stories 12/07/22 Cytokinetics initiates Phase 1 clinical study of CK-3828136 $292.32 / +4.085 (+1.42%)
12/06/22 Accenture announces sustainability collaboration with Planet Labs 12/01/22 Accenture acquires Fiftyfive5 11/15/22 Accenture to acquire Albert Inc., terms undisclosed 11/03/22 Accenture names Andrew Levy chief corporate, government affairs officer 12/11/22 Adicet Bio reports data from ongoing ADI-001 Phase 1 trial 11/29/22 Adicet Bio appoints Nancy Boman, M.D Chief Regulatory Officer 10/17/22 RA Capital Management reports 5.5% passive stake in Adicet Bio $276.76 / -1.825 (-0.66%)
12/13/22 BMO Capital Horizon Therapeutics downgraded to Market Perform from Outperform at BMO Capital 12/13/22 Baird Amgen deal yields nice accretion but large debt position, says Baird 12/13/22 Wells Fargo Horizon Therapeutics downgraded to Equal Weight from Overweight at Wells Fargo 12/13/22 Guggenheim Horizon Therapeutics downgraded to Neutral from Buy at Guggenheim HZNP Horizon Therapeutics $112.34 / +14.995 (+15.40%)
$78.62 / +16.54 (+26.64%)
12/13/22 Needham Coupa Software downgraded to Hold from Buy at Needham 12/13/22 Wells Fargo Coupa Software price target raised to $81 from $65 at Wells Fargo 12/13/22 Needham Coupa Software downgraded to Hold from Buy at Needham 12/13/22 Wolfe Research Coupa Software downgraded to Peer Perform from Outperform at Wolfe Research 12/12/22 Credit Suisse Credit Suisse views Weber go-private deal 'positively' 10/25/22 Wells Fargo Weber upgraded to Equal Weight from Underweight at Wells Fargo 08/17/22 Citi Weber downgraded to Sell from Neutral at Citi 08/16/22 BMO Capital Weber price target lowered to $6 from $7 at BMO Capital 12/13/22 Canaccord Rivian Automotive production pause preserves capital, says Canaccord 12/13/22 Baird Rivian Automotive price target lowered to $44 from $51 at Baird 11/29/22 Evercore ISI Rivian Automotive initiated with an In Line, $35 target at Evercore ISI 11/29/22 Evercore ISI Rivian Automotive initiated with an In Line at Evercore ISI $103.78 / +2.175 (+2.14%)
11/23/22 Morgan Stanley CVS Health assumed with an Overweight at Morgan Stanley 11/21/22 Credit Suisse CVS Health price target raised to $125 from $117 at Credit Suisse 11/06/22 Raymond James CVS Health price target lowered to $115 from $120 at Raymond James 11/02/22 B. Riley B. Riley downgrades Semler Scientific on risk from Signify buyout WBA Walgreens Boots Alliance 11/23/22 Morgan Stanley Walgreens Boots Alliance assumed with an Underweight at Morgan Stanley 11/22/22 Cowen Walgreens upgraded to Outperform on services transition at Cowen 11/22/22 Cowen Walgreens Boots Alliance upgraded to Outperform from Market Perform at Cowen 11/18/22 JPMorgan Walgreens Boots Alliance upgraded to Overweight from Neutral at JPMorgan 12/12/22 Deutsche Bank Micron downgraded to Hold from Buy at Deutsche Bank 12/07/22 Wells Fargo Micron price target lowered to $70 from $75 at Wells Fargo 12/05/22 Lynx Micron price target raised to $60 from $56 at Lynx 11/30/22 Stifel Micron management's tone 'incrementally downbeat,' says Stifel 12/12/22 Stifel Under Armour upgraded to Buy from Hold at Stifel 11/07/22 JPMorgan Under Armour price target raised to $11 from $10 at JPMorgan 11/01/22 BofA Under Armour reinstated with a Neutral at BofA 10/31/22 JPMorgan Under Armour price target lowered to $10 from $12 at JPMorgan 12/12/22 Wells Fargo Wells Fargo downgrades Qualcomm to Underweight with $105 price target 12/12/22 Wells Fargo Qualcomm downgraded to Underweight from Equal Weight at Wells Fargo 11/15/22 Credit Suisse Qualcomm initiated with an Outperform at Credit Suisse 11/03/22 KeyBanc Qualcomm price target lowered to $150 from $170 at KeyBanc $292.32 / +4.085 (+1.42%)
12/12/22 Piper Sandler Accenture downgraded to Underweight from Neutral at Piper Sandler 10/14/22 JPMorgan Accenture price target lowered to $306 from $329 at JPMorgan 10/13/22 Wells Fargo Wells sees some encouraging signs from emerging metaverse app economy 09/27/22 Alliance Global Partners Perficient upgraded to Buy from Neutral at Alliance Global Partners 12/13/22 Morgan Stanley Nike price target raised to $127 from $120 at Morgan Stanley 12/12/22 Goldman Sachs Tapestry upgraded to Buy from Neutral at Goldman Sachs 11/29/22 JPMorgan Tapestry price target raised to $47 from $46 at JPMorgan 11/14/22 Citi Tapestry price target lowered to $40 from $42 at Citi $253.52 / -20.82 (-7.59%)
12/13/22 Needham Williams-Sonoma initiated with a Hold at Needham 12/12/22 Cowen RH price target lowered to $320 from $350 at Cowen 12/12/22 Loop Capital RH price target lowered to $370 from $420 at Loop Capital 12/12/22 Barclays RH price target raised to $254 from $243 at Barclays 12/12/22 Goldman Sachs Levi Strauss downgraded to Neutral from Buy at Goldman Sachs 11/29/22 JPMorgan Levi Strauss price target lowered to $19 from $20 at JPMorgan 10/10/22 Citi Levi Strauss price target lowered to $19 from $27 at Citi 10/07/22 Guggenheim Levi Strauss price target lowered to $27 from $33 at Guggenheim 12/12/22 KeyBanc Coinbase initiated with a Sector Weight at KeyBanc 12/12/22 Mizuho Fiserv price target lowered to $135 from $145 at Mizuho 12/09/22 Mizuho Coinbase downgraded to Underperform from Neutral at Mizuho 12/05/22 Atlantic Equities Coinbase price target lowered to $46 from $67 at Atlantic Equities 11/25/22 William Blair Report about Galaxy S23 'significant positive' for Iridium, says William Blair 08/22/22 Loop Capital Enovix price target raised to $100 from $50 at Loop Capital 08/11/22 Loop Capital Loop Capital has 'stronger conviction' in Enovix after 'customer milestones' 06/22/22 Loop Capital Samsung initiated with a Buy at Loop Capital 12/09/22 BofA BofA upgrades Credit Suisse to Buy, sees more than 20% upside potential 12/09/22 BofA Credit Suisse upgraded to Buy from Neutral at BofA 12/01/22 JPMorgan Credit Suisse price target lowered to CHF 3.80 from CHF 5.50 at JPMorgan 11/07/22 AlphaValue/Baader Credit Suisse downgraded to Sell from Buy at AlphaValue/Baader 12/08/22 Citi DoD contracts shows competitiveness of cloud industry, says Citi 12/07/22 BTIG SentinelOne price target lowered to $20 from $25 at BTIG 12/01/22 BMO Capital Okta price target raised to $69 from $58 at BMO Capital 12/01/22 Wedbush Activision Blizzard added to Best Ideas List at Wedbush 11/15/22 Mizuho VMware price target lowered to $135 from $138 at Mizuho 10/17/22 Needham Nutanix price target raised to $31 from $25 at Needham 10/17/22 Northland Salesforce initiated with a Market Perform at Northland 07/06/22 Raymond James VMware downgraded to Market Perform from Outperform at Raymond James 02/02/22 Maxim Pitney Bowes price target lowered to $7 from $12 at Maxim 12/12/22 RBC Capital Coupa Software upgraded to Sector Perform from Underperform at RBC Capital 12/12/22 JPMorgan JPMorgan upgrades 'undervalued profitable growth story' Box to buy 12/12/22 JPMorgan Box upgraded to Overweight from Neutral at JPMorgan 11/21/22 Credit Suisse Box initiated with an Outperform at Credit Suisse 12/12/22 H.C. Wainwright Adicet Bio price target raised to $38 from $34 at H.C. Wainwright 09/21/22 JPMorgan Adicet Bio initiated with Overweight, $23 target at JPMorgan 09/21/22 JPMorgan Adicet Bio initiated with an Overweight at JPMorgan 03/30/22 SMBC Nikko Adicet Bio initiated with an Outperform at SMBC Nikko 11/04/22 RBC Capital Karyopharm upgraded to Outperform from Sector Perform at RBC Capital 11/04/22 RBC Capital Karyopharm upgraded to Outperform from Sector Perform at RBC Capital 08/05/22 Baird Karyopharm price target lowered to $14 from $17 at Baird 08/05/22 Barclays Karyopharm price target lowered to $8 from $14 at Barclays 12/12/22 Oppenheimer Fate Therapeutics price target lowered to $65 from $90 at Oppenheimer 11/16/22 Citi Fate Therapeutics price target lowered to $80 from $87 at Citi 11/04/22 Cantor Fitzgerald Fate Therapeutics assumed with an Overweight at Cantor Fitzgerald 10/10/22 Canaccord Fate Therapeutics initiated with a Buy at Canaccord 09/13/22 H.C. Wainwright GT Biopharma price target lowered to $5 from $25 at H.C. Wainwright 08/11/22 Roth MKM Roth cuts GT Biopharma to Neutral after filings for TriKE programs pushed back 08/11/22 Roth MKM GT Biopharma downgraded to Neutral from Buy at Roth Capital 01/24/22 B. Riley GT Biopharma price target lowered to $18 from $26 at B. Riley 11/21/22 Cowen Whole Earth Brands price target lowered to $11 from $14 at Cowen 11/10/22 Canaccord Whole Earth Brands price target lowered to $8 from $10 at Canaccord 03/15/22 Lake Street Whole Earth Brands price target lowered to $16 from $19 at Lake Street 03/15/22 Cantor Fitzgerald Whole Earth Brands price target lowered to $19.00 from $24.75 at Cantor Fitzgerald 07/11/22 Rosenblatt Universal Technical initiated with a Buy at Rosenblatt 06/28/22 Argus Argus upgrades Universal Technical to Buy on expansion efforts, valuation 06/28/22 Argus Universal Technical upgraded to Buy from Hold at Argus 05/05/22 Barrington Universal Technical price target raised to $14 from $10 at Barrington 04/27/22 Jefferies Dynagas LNG reinstated with a Hold at Jefferies 12/09/22 Credit Suisse Pembina Pipeline downgraded to Neutral from Outperform at Credit Suisse 11/07/22 National Bank Pembina Pipeline price target raised to C$46 from C$45 at National Bank 11/04/22 Raymond James Pembina Pipeline price target lowered to C$46 from C$49 at Raymond James 10/20/22 Scotiabank Pembina Pipeline price target lowered to C$50 from C$55 at Scotiabank 08/15/22 Weber reports Q3 EPS (41c) 07/25/22 Weber withdraws FY22 guidance, suspends dividend 07/25/22 Weber sees Q3 revenue $525M-$530M, consensus $532.74M WBA Walgreens Boots Alliance 10/13/22 Walgreens Boots Alliance sees FY23 adjusted EPS $4.45-$4.65, consensus $5.01 10/13/22 Walgreens Boots Alliance reports Q4 adjusted EPS 80c, consensus 77c 10/12/22 Notable companies reporting before tomorrow's open 06/30/22 Walgreens Boots Alliance backs FY22 EPS outlook of low single digit growth 11/22/22 VMware reports Q3 adjusted EPS $1.47, consensus $1.58 08/25/22 VMware reports Q2 adjusted EPS $1.64 vs $1.75 last year 08/25/22 Notable companies reporting after market close 12/12/22 Virco reports Q3 EPS 48c vs. 8c last year 12/12/22 Universal Technical reports Q4 EPS 3c vs 20c last year 11/21/22 Universal Technical sees FY22 revenue $418.8M, consensus $418.98M 08/03/22 Universal Technical narrows FY22 revenue view to $410M-$420M from $405.0M-$420M 08/03/22 Universal Technical reports Q3 EPS (1c) vs. 3c a year ago 11/03/22 Under Armour cuts FY23 EPS view to 56c-60c from 61c-67c, consensus 43c 11/03/22 Under Armour reports Q2 adjusted EPS 20c, consensus 16c 11/02/22 Notable companies reporting before tomorrow's open 11/10/22 Tapestry sees FY23 EPS $3.60-$3.70, consensus $3.82 11/10/22 Tapestry reports Q1 EPS 79c, consensus 75c 11/09/22 Notable companies reporting before tomorrow's open 10/26/22 Samsung reports Q3 net profit KRW 9.39T vs. KRW 12.29T last year 10/06/22 Samsung sees Q3 operating profit KRW10.8T vs. KRW12.1T consensus 07/28/22 Samsung reports Q2 EPS KRW 1,613 vs. KRW 1,391 last year 07/06/22 Samsung sees Q2 operating profit KRW14.0T vs. KRW14.6T consensus 11/09/22 Rivian Automotive reports Q3 adjusted EPS ($1.57), consensus ($1.82) 11/09/22 Notable companies reporting after market close 10/27/22 Amazon reports Q3 EPS 28c with Rivian gain, consensus 21c 08/11/22 Rivian Automotive reports Q2 EPS ($1.89), consensus ($1.67) $253.52 / -20.82 (-7.59%)
12/08/22 RH narrow FY22 revenue growth view to down 4.5% to down 3.5% 12/08/22 RH reports Q3 EPS $5.67, consensus $4.70 12/08/22 Notable companies reporting after market close 09/08/22 RH sees Q3 revenue down 18% to down 15% 11/02/22 Qualcomm sees Q1 adjusted EPS adjusted EPS $2.25-$2.45, consensus $3.42 11/02/22 Qualcomm reports Q4 adjusted EPS $3.13, consensus $3.13 11/02/22 Notable companies reporting after market close 07/27/22 Qualcomm sees Q4 adjusted EPS $3.00-$3.30, consensus $3.23 11/01/22 PBI backs FY22 revenue view down low-single digits to up low single digits 11/01/22 Pitney Bowes reports Q3 adjusted EPS 0c, consensus 2c 12/12/22 Pembina Pipeline sees FY23 adjusted EBITDA C$3.5B-C$3.8B 11/03/22 Pembina Pipeline reports Q3 EPS C$3.23 vs. C$1.01 a year ago 08/04/22 Pembina Pipeline raises FY22 adjusted EBITDA view to C$3.575B-C$3.675B 08/04/22 Pembina Pipeline reports Q2 EPS C$0.69 vs. C$0.39 a year ago 09/29/22 Micron sees Q2 revenue range similar to Q1 09/29/22 Micron sees Q1 adjusted EPS 4c, plus or minus 10c, consensus 64 09/29/22 Micron reports Q4 adjusted EPS $1.45, consensus $1.30 09/29/22 Notable companies reporting after market close 10/25/22 Microsoft sees FX decreasing total revenue growth by 5% in FY23 10/25/22 Microsoft reports Q1 EPS $2.35, consensus $2.30 10/25/22 Notable companies reporting after market close 07/26/22 Microsoft sees FY23 revenue growth in double digits, consensus $225.98B 10/06/22 Levi Strauss cuts FY22 EPS view to $1.44-$1.49 from $1.50-$1.56 10/06/22 Levi Strauss reports Q3 EPS 40c, consensus 37c 07/07/22 Levi Strauss backs FY22 adjusted EPS view $1.50-$1.56, consensus $1.55 07/07/22 Levi Strauss reports Q2 adjusted EPS 29c, consensus 23c 11/03/22 Karyopharm sees FY22 revenue $155M-$165M, consensus $157.23M 11/03/22 Karyopharm reports Q3 EPS (45) with items, consensus (57c) 08/04/22 Karyopharm sees 2022 revenue $155M-$165M, consensus $160.03M 08/04/22 Karyopharm reports Q2 EPS (62c), consensus (63c) HZNP Horizon Therapeutics $112.34 / +14.995 (+15.40%)
11/02/22 Horizon Therapeutics sees FY22 revenue s $3.59B-$3.61B, consensus $3.56B 11/02/22 Horizon Therapeutics reports Q3 EPS $1.25, consensus $1.01 08/03/22 Horizon Therapeutics cuts FY22 revenue view to $3.53B-$3.6B from $3.9B-$4B 08/03/22 Horizon Therapeutics reports Q2 adjusted EPS $1.07, consensus $1.35 12/12/22 Whole Earth Brands reaffirms 2022 guidance 11/09/22 Whole Earth Brands sees 2022 revenue $535M-$545M, consensus $535.57M 11/09/22 Whole Earth Brands reports Q3 EPS (6c), consensus 8c 08/09/22 Whole Earth Brands reiterates FY22 revenue view $530M-$545M, consensus $536.83M 11/03/22 Fate Therapeutics reports Q3 EPS (86c), consensus (89c) 08/03/22 Fate Therapeutics reports Q2 EPS (79c), consensus (83c) 12/12/22 Dynagas LNG reports Q3 adjusted EPS 4c vs. 24c last year 09/22/22 Dynagas LNG reports Q2 EPS 17c vs. 20c in last year's quarter $103.78 / +2.175 (+2.14%)
11/02/22 CVS Health sees FY23 adjusted EPS $8.70-$8.90, consensus $9.06 11/02/22 CVS Health raises FY22 revenue view to $309B-$314B from $307B-$312B 11/02/22 CVS Health raises FY22 adjusted EPS view to $8.55-$8.65 from $8.40-$8.60 11/02/22 CVS Health reports Q3 adjusted EPS $2.09, consensus $1.99 10/27/22 Credit Suisse reports Q3 net revenue CHF 3.8B vs. CHF 5.43B last year 07/27/22 Credit Suisse reports Q2 net revenue CHF3.6B vs. CHF5.1B last year $78.62 / +16.54 (+26.64%)
12/12/22 Coupa Software reports Q3 non-GAAP EPS 15c, consensus 10c 09/06/22 Coupa Software sees FY23 non-GAAP EPS 37c-44c, consensus 26c 09/06/22 Coupa Software sees Q3 non-GAAP EPS 8c-10c, consensus 6c 09/06/22 Coupa Software reports Q2 non-GAAP EPS 20c, consensus 9c 12/07/22 Coinbase CEO tells Bloomberg 2022 revenue seen down 50% or more 11/03/22 Coinbase reports Q3 EPS ($2.43), consensus ($2.40) 08/09/22 Coinbase reports Q2 EPS ($4.98), consensus ($2.65) 11/30/22 Box raises FY23 EPS view to $1.16-$1.17 from $1.13-$1.16, consensus $1.14 11/30/22 Box sees Q4 adjusted EPS 34c-35c, consensus 33c 11/30/22 Box reports Q3 adjusted EPS 31c, consensus 30c 11/30/22 Notable companies reporting after market close $276.76 / -1.825 (-0.66%)
11/03/22 Amgen narrows FY22 adjusted EPS view to $17.25-$17.85 from $17.00-$18.00 11/03/22 Amgen reports Q3 adjusted EPS $4.70, consensus $4.44 11/03/22 Notable companies reporting after market close 08/04/22 Amgen backs FY22 adjusted EPS view $17.00-$18.00, consensus $17.40 $292.32 / +4.085 (+1.42%)
09/22/22 Accenture sees Q1 revenue $15.2B-$15.75B, consensus $16.06B 09/22/22 Accenture sees FY23 EPS $11.09-$11.41, consensus $12.00 09/22/22 Accenture reports Q4 EPS $2.60, consensus $2.58 06/23/22 Accenture sees Q4 revenue $15B-$15.5B, consensus $14.83B 11/08/22 Adicet Bio reports Q3 EPS (53c), consensus (53c) 08/10/22 Adicet Bio reports Q2 EPS (56c), consensus (45c) 10/11/22 Weber considering debt financing from shareholder BDT, Bloomberg reports 10/11/22 Weber received private equity takeover approach, Street Insider says 06/23/22 Weber, Traeger rallies punish short sellers, Bloomberg says WBA Walgreens Boots Alliance 11/07/22 Walgreens-backed VillageMD close to $9B deal with Summit, WSJ reports 11/01/22 Walgreens, Walmart, CVS reach $12B opioid settlement deal, Bloomberg reports 11/01/22 Walgreens-backed VillageMD in talks to merge with Summit, Bloomberg reports 10/02/22 Walgreens turns to prescription-filling robots to free up pharmacists, WSJ says 12/12/22 Three top executives to leave VMware, WSJ reports 12/09/22 Broadcom facing antitrust investigation by EU into VMware deal, Reuters says 12/09/22 Broadcom facing antitrust investigation by EU into VMware deal, Reuters reports 10/16/22 Broadcom banks on early EU approval of $61B VMware deal, Reuters says 09/14/22 Steph Curry said to be near $1B lifetime deal with Under Armour, Tribune reports 07/29/22 Under Armour pays $67.5M to settle UCLA lawsuit, LA Times says 12/03/22 Tapestry, Saia among small-cap stocks set for big gains, Barron's says 10/13/22 Samsung granted one-year exemption from new U.S. chip restrictions, WSJ reports 11/12/22 EV stocks face a reckoning, not all will survive, Barron's says 11/07/22 Amazon has 'hundreds' of Rivian vans making deliveries, The Verge reports 10/19/22 Rivian has fixed 'majority' of recalled vehicles, TechCrunch reports 08/19/22 Rivian drops cheapest version of electric pickup truck, Bloomberg reports 12/08/22 Qualcomm ends major program, SemiAccurate reports 11/17/22 TSMC to make latest Qualcomm flagship smartphone chips, DigiTimes reports 11/02/22 Qualcomm implements hiring freeze, CNBC reports 12/12/22 Samsung to maintain memory output ramp-up, DigiTimes reports 11/29/22 Micron to ramp up 1-beta DRAM shipments by end of year, DigiTimes reports 10/06/22 Restrictions on China chipmakers won't target SK Hynix and Samsung, Reuters says 10/06/22 U.S. to effectively halt some NAND, DRAM equipment export to China, Reuters says 12/12/22 Microsoft made concession offer to EU over antitrust concerns, Reuters says 12/12/22 Microsoft seeks to settle EU concerns about business practices, Reuters reports 12/11/22 FTC tussle with Microsoft puts spotlight on cloud gaming, WSJ says 12/10/22 Microsoft, Arista among stocks that can survive a triple whammy, Barron's says HZNP Horizon Therapeutics $112.34 / +14.995 (+15.40%)
12/04/22 J&J says won't make offer for Horizon Therapeutics, Bloomberg reports 11/04/22 Barclays' boosted stake in Horizon Therapeutics 'interesting,' DealReporter says 10/14/22 U.K. in talks with U.S. LNG producers over purchase agreements, Sky News says $103.78 / +2.175 (+2.14%)
12/10/22 CVS big bet on primary care hasn't yet come to pass, Barron's says 12/04/22 CVS testing remote system to help fill prescriptions, WSJ reports 11/29/22 Managed care company returns will be tough to keep replicating, WSJ says 11/20/22 JPMorgan taps Walmart exec for new health venture, Bloomberg says 12/12/22 Credit Suisse accepted 'suspicious' invoices for Greensill loan, FT reports 12/05/22 Credit Suisse chairman says outflows have 'stabilised,' Reuters reports 12/04/22 Credit Suisse's investment bank spinoff attracts Saudi Crown Prince, WSJ says 12/01/22 Credit Suisse eyes ways to accelerate cost cuts, Reuters reports $78.62 / +16.54 (+26.64%)
11/23/22 Vista Equity Partners exploring deal to buy Coupa Software, Bloomberg says 11/23/22 Vista Equity exploring deal to buy Coupa Software, Bloomberg says 11/23/22 Vista Equity exploring acquisition of Coupa Software, Bloomberg says 12/12/22 Coinbase CEO Armstrong believes regulation will boost USD Coin use, WSJ reports 12/07/22 Coinbase CEO tells Bloomberg 2022 revenue seen down 50% or more 11/19/22 Crypto's survival may now depend on Washington, Barron's says 11/13/22 At least $1B of client funds missing at FTX, Reuters reports $276.76 / -1.825 (-0.66%)
12/11/22 Amgen nears deal to acquire Horizon Therapeutics, WSJ reports 11/04/22 Supreme Court to hear Amgen appeal in Repatha patent dispute, Bloomberg says 08/01/22 Amgen battles IRS over $10.7B in back taxes, WSJ reports $292.32 / +4.085 (+1.42%)
12/05/22 Allstate replacing Accenture's Droga5 for creative account, AdAge reports 11/04/22 Short Report: Bears keen to further pile on credit lending names WBA Walgreens Boots Alliance 11/26/22 Buy/Sell: Wall Street's top 10 stock calls this week 11/22/22 What You Missed On Wall Street On Tuesday 11/22/22 What You Missed On Wall Street This Morning 11/23/22 What You Missed On Wall Street On Wednesday 11/23/22 What You Missed On Wall Street This Morning 11/21/22 What You Missed On Wall Street On Monday 11/21/22 What You Missed On Wall Street This Morning 08/18/22 What You Missed On Wall Street On Thursday 10/04/22 What You Missed On Wall Street On Tuesday 09/21/22 What You Missed On Wall Street On Wednesday 12/12/22 What You Missed This Week in EVs and Clean Energy $253.52 / -20.82 (-7.59%)
12/09/22 What You Missed On Wall Street On Friday 12/09/22 What You Missed On Wall Street This Morning 12/12/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 12/09/22 Fly Intel: Pre-market Movers 12/08/22 What You Missed On Wall Street On Thursday 11/08/22 What You Missed On Wall Street On Tuesday 11/08/22 What You Missed On Wall Street This Morning HZNP Horizon Therapeutics $112.34 / +14.995 (+15.40%)
12/12/22 Fly Intel: Pre-market Movers 12/05/22 What You Missed On Wall Street On Monday 11/04/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 09/23/22 Fly Intel: Pre-market Movers 09/22/22 Fly Intel: After-Hours Movers $103.78 / +2.175 (+2.14%)
12/05/22 What You Missed On Wall Street This Morning 11/23/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 12/09/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations $78.62 / +16.54 (+26.64%)
11/25/22 What You Missed On Wall Street On Friday 12/12/22 Fly Insider: comScore, Donegal Group among week's notable insider trades 10/03/22 What You Missed On Wall Street On Monday 10/03/22 What You Missed On Wall Street This Morning $276.76 / -1.825 (-0.66%)
12/12/22 What You Missed On Wall Street On Monday 12/12/22 What You Missed On Wall Street This Morning 11/30/22 What You Missed On Wall Street On Wednesday 11/30/22 What You Missed On Wall Street This Morning $292.32 / +4.085 (+1.42%)
09/22/22 What You Missed On Wall Street On Thursday 11/23/22 Largest borrow rate increases among liquid names 11/02/22 Largest borrow rate increases among liquid names 11/01/22 Largest borrow rate increases among liquid names 10/31/22 Largest borrow rate increases among liquid names WBA Walgreens Boots Alliance 11/11/22 Unusually active option classes on open November 11th 11/07/22 Early notable gainers among liquid option names on November 7th 11/07/22 Unusually active option classes on open November 7th 10/13/22 Early notable gainers among liquid option names on October 13th 08/25/22 VMware options imply 1.2% move in share price post-earnings 10/31/22 Under Armour Class A call volume above normal and directionally bullish 10/10/22 Under Armour Class A call volume above normal and directionally bullish 08/03/22 Unusually active option classes on open August 3rd 06/30/22 Under Armour Class A put volume heavy and directionally bearish 11/04/22 Unusually active option classes on open November 4th 09/12/22 Early notable gainers among liquid option names on September 12th 09/01/22 Tapestry call volume above normal and directionally bullish 11/09/22 Rivian options imply 10.8% move in share price post-earnings 10/10/22 Unusually active option classes on open October 10th 10/06/22 Unusually active option classes on open October 6th 09/29/22 Unusually active option classes on open September 29th $253.52 / -20.82 (-7.59%)
12/08/22 Restoration Hardware options imply 7.8% move in share price post-earnings 10/24/22 Restoration Hardware put volume heavy and directionally bearish 09/08/22 Restoration Hardware options imply 7.3% move in share price post-earnings 09/06/22 Restoration Hardware call volume above normal and directionally bullish 08/31/22 Qualcomm sued by Arm for contract breach, infringement, Bloomberg says 07/27/22 Qualcomm options imply 6.3% move in share price post-earnings 06/27/22 Qualcomm call volume above normal and directionally bullish 06/13/22 Qualcomm call volume above normal and directionally bullish 09/29/22 Micron options imply 5.2% move in share price post-earnings 09/01/22 Micron put volume heavy and directionally bearish 08/15/22 Micron call volume above normal and directionally bullish 08/09/22 Unusually active option classes on open August 9th 12/12/22 Early notable gainers among liquid option names on December 12th 11/10/22 Microsoft put buyer realizes 13% same-day gains 10/25/22 Microsoft options imply 3.9% move in share price post-earnings 09/16/22 Microsoft put buyer realizes 22% same-day gains 10/19/22 Levi Strauss call volume above normal and directionally bullish 10/06/22 Levi Strauss options imply 7.1% move in share price post-earnings 07/07/22 Levi Strauss options imply 6.6% move in share price post-earnings HZNP Horizon Therapeutics $112.34 / +14.995 (+15.40%)
12/12/22 Unusually active option classes on open December 12th 12/02/22 Horizon Pharma put volume heavy and directionally bearish 11/30/22 Unusually active option classes on open November 30th $103.78 / +2.175 (+2.14%)
11/28/22 CVS Health put volume heavy and directionally bearish 11/02/22 Unusually active option classes on open November 2nd 10/19/22 Unusually active option classes on open October 19th 09/13/22 CVS Health call volume above normal and directionally bullish 12/12/22 Notable open interest changes for December 12th 12/02/22 Unusually active option classes on open December 2nd $78.62 / +16.54 (+26.64%)
11/07/22 Coupa Software put volume heavy and directionally bearish 11/04/22 Coupa Software put volume heavy and directionally bearish 11/03/22 Coupa Software put volume heavy and directionally bearish 11/01/22 Coupa Software call volume above normal and directionally bullish 11/18/22 Coinbase put volume heavy and directionally bearish 11/09/22 Unusually active option classes on open November 9th 11/09/22 Notable open interest changes for November 9th 11/08/22 Coinbase put buyer realizes 72% same-day gains 11/30/22 Box options imply 5.4% move in share price post-earnings 08/24/22 Box options imply 4.5% move in share price post-earnings $276.76 / -1.825 (-0.66%)
10/11/22 Early notable gainers among liquid option names on October 11th 07/12/22 Amgen put volume heavy and directionally bearish 06/27/22 Amgen put volume heavy and directionally bearish
On The Fly
Get caught up quickly on…
Show Hide Related Items >> <<
12/12/22 Weber rises 23.3% 12/12/22 Weber rises 23.3% 12/12/22 Weber rises 23.1% 12/12/22 Weber to be taken private by BDT Capital in $8.05 per share transaction 12/12/22 Meridian Bioscience announces anticipated closing date of pending merger 11/22/22 Meridian Bioscience expects to complete merger with SDB, SJL by end of 2022 10/11/22 Meridian says CFIUS application accepted for review, working with DoJ on probe 07/29/22 Meridian receives re-authorization of its EUA for Revogene assay from FDA 12/12/22 Universal Technical falls -16.3% 12/12/22 Universal Technical falls -10.6% 12/12/22 Universal Technical trading resumes 12/12/22 Universal Technical trading halted, volatility trading pause 11/18/22 Adtalem Global Education appoints Blake Simpson as CCO 10/05/22 Under Armour announces executive leadership changes 08/03/22 Under Armour sees 'overabundance' of product hitting the market in 2022 08/03/22 Under Armour's Plank says Browne in running for permanent CEO job 12/04/22 Fly Intel: Top five weekend stock stories 09/09/22 Tapestry announces long-term financial targets 08/04/22 Tapestry COO Tom Glaser retires, Scott Roe to succeed 11/09/22 Cinedigm reaches new distribution agreement with Samsung 11/03/22 ironSource announces expansion of partnership with Samsung 10/31/22 Rambus and Samsung extend comprehensive pact for additional 10 years 10/20/22 Verizon starts orders for Samsung Galaxy XCover6 Pro 12/12/22 Rivian Automotive pauses plans to produce electric commercial vans in Europe 12/06/22 Vietnam-based EV maker VinFast plans for U.S. IPO 12/05/22 Rivian Automotive enters wind energy deal with Apex Clean Energy 11/14/22 Soros Fund Management buys Sierra Wireless, exits Kinder Morgan in Q3 $252.26 / -22.08 (-8.05%)
12/08/22 RH says Q3 gross margin contracted 50bps 12/08/22 RH to acquire Dmitriy & Co 12/08/22 RH CEO to exercise expiring options 11/14/22 Berkshire Hathaway adds TSMC, exits STORE Capital in Q3 11/02/22 Qualcomm falls 7% to $104.90 after Q1 guidance misses estimates 11/02/22 Qualcomm sees low-double digits handset volume declines for 2022 10/25/22 Cognizant expands collaboration with Qualcomm 09/30/22 L&T Technology Services, Qualcomm collaborate to deploy end-to-end 5G solutions 11/18/22 Pembina Pipeline announces settlement agreement with Ruby Pipeline 10/18/22 TC Energy, Pembina Pipeline enter into carbon sequestration evaluation agreement 08/25/22 Pembina Pipeline appoints Cameron Goldade as CFO 08/15/22 Pembina Pipeline completes transaction with KKR to create PGI 12/12/22 Inotiv: Q1 earnings, liquidity could be impacted by Cambodian NHPs 12/08/22 Inotiv announces new site openings, capacity expansion 11/29/22 Inotiv announces facilities consolidations plans 11/18/22 Inotiv trading resumes 12/06/22 Micron ships Micron 2550 NVMe SSD to global PC OEM customers 11/29/22 Micron CFO says pricing has trended 'well below' expectations 11/16/22 Micron down 5% after warning outlook for 2023 has weakened 11/16/22 Micron announces further actions to address market conditions 12/12/22 Thomson Reuters, Blackstone to sell shares of LSEG to Microsoft 12/12/22 Microsoft to buy 4% stake in LSEG amid 10-year cloud partnership 12/09/22 Amazon, Bandai Namco partner over release of 'Blue Protocol' in 2023 11/08/22 Levi Strauss appoints Michelle Gass as President, to succeed Bergh as CEO 10/07/22 Levi Strauss falls -7.4% 10/06/22 Levi Strauss falls 3% to $15.40 after Q3 earnings, FY22 guidance cut 07/28/22 Kohl's becomes 'exclusive' wholesale retailer for Levi's SilverTab collection 12/12/22 Karyopharm announces updated results from Phase 1 selinexor data 11/03/22 Karyopharm to present new selinexor data in myelofibrosis and myeloma 11/01/22 Karyopharm, Menarini Group: EC grants orphan designation for selinexor 10/31/22 Karyopharm and Menarini announce EC granted orphan designation for selinexor 12/08/22 IAC reports November Angi Inc. total revenue up 5% from last year 11/08/22 IAC CEO says 'will fix mistakes' at both IAC and Angi 11/07/22 Barry Diller tells CNBC he hopes Netflix stays independent HZNP Horizon Therapeutics $112.03 / +14.68 (+15.08%)
12/11/22 Sanofi does not intend to make offer for Horizon Therapeutics 11/10/22 GT Biopharma CEO says 'pleased with progress' with TriKE platform 09/12/22 GT Biopharma announces highlights from GTB-5550 study 11/17/22 Gap rises 8% to nearly $14 after Q3 results 11/10/22 Gap launches collection of 'family essentials' with Amazon Fashion 10/25/22 Gap 'taking immediate steps' to remove Yeezy Gap product from stores 09/28/22 Gap unit Athleta teams with thredUP, and Shop Premium Outlets for online 12/12/22 Whole Earth Brands CEO Albert Manzone steps down 07/28/22 Swerve launches next generation of sugar alternative products 06/21/22 Whole Earth Brands announces global strategic ESG goals for 2030 06/17/22 Whole Earth Brands increases revolving credit facility to $125M 12/12/22 GT Biopharma, Fate present preclinical data on dual antigen targeting approach 12/11/22 Fate presents interim data from dose-escalation stage of Phase 1 study of FT819 12/11/22 Fate presents interim clinical data from ongoing Phase 1 stuty of FT576 11/07/22 Fate announces exercise by ONO of option to FT825/ONO-8250 12/05/22 Dynagas LNG reports new U.S. tax rules on PTPs don't affect unit holders 06/27/22 Dynagas LNG reports Q1 EPS 18c vs. 21c in Q1 last year 12/02/22 Credit Suisse rallies after Chairman says outflows 'basically stopped' 11/23/22 Credit Suisse sees likely loss for Wealth Management in Q4 11/23/22 Credit Suisse sees 'substantial' loss of up to CHF 1.5B in Q4 11/23/22 Credit Suisse confirms capital ratio guidance from October 27 $78.70 / +16.62 (+26.77%)
12/12/22 Coupa Software to be acquired by Thoma Bravo for $81 per share in cash 11/23/22 Coupa Software up 34% after takeover report triggered halt 11/23/22 Coupa Software trading resumes 11/23/22 Coupa halted for volatility after jumping 10% on Bloomberg report 12/02/22 Coinbase says Apple blocked last app release on NFTs 11/30/22 Coinbase Wallet to stop supporting BCH, ETC, XLM, XRP 11/21/22 Crypto names down in pre-market as bitcoin falls to one-week low 11/16/22 Cathie Wood's ARK Investment bought 245.6K shares of Coinbase today 10/19/22 Box renews partnership with Japan's Ministry of the Environment 08/24/22 Box reports Q2 RPOs up 14% y/y at $1.05B 08/18/22 Box announces appointment of Walia to board of directors 06/23/22 Box announces collaboration with Fujifilm Business 12/08/22 Activision Blizzard CEO confident Microsoft deal will close 12/08/22 Microsoft's Smith has 'complete confidence' in case regarding Activision deal 12/08/22 FTC announces suit seeking to block Microsoft from buying Activision 12/08/22 Activision falls 2% to $74.05 after Bloomberg report of FTC suit $275.13 / -3.455 (-1.24%)
12/12/22 Amgen to acquire Horizon Therapeutics for $116.50 per share in cash 12/12/22 Amgen to acquire Horizon Therapeutics for $116.50 per share in cash 12/11/22 Fly Intel: Top five weekend stock stories 12/07/22 Cytokinetics initiates Phase 1 clinical study of CK-3828136 12/06/22 Accenture announces sustainability collaboration with Planet Labs 12/01/22 Accenture acquires Fiftyfive5 11/15/22 Accenture to acquire Albert Inc., terms undisclosed 11/03/22 Accenture names Andrew Levy chief corporate, government affairs officer 12/11/22 Adicet Bio reports data from ongoing ADI-001 Phase 1 trial 11/29/22 Adicet Bio appoints Nancy Boman, M.D Chief Regulatory Officer 10/17/22 RA Capital Management reports 5.5% passive stake in Adicet Bio $275.13 / -3.455 (-1.24%)
12/12/22 Stifel Horizon Therapeutics downgraded to Hold from Buy at Stifel 12/07/22 Piper Sandler Horizon Therapeutics price target raised to $110 from $90 at Piper Sandler 12/06/22 Oppenheimer Amgen price target raised to $310 from $300 at Oppenheimer 12/05/22 Piper Sandler Amgen price target raised to $297 from $278 at Piper Sandler HZNP Horizon Therapeutics $112.03 / +14.68 (+15.08%)
12/01/22 Jefferies Horizon Therapeutics price target raised to $125 from $101 at Jefferies 11/30/22 Cowen Horizon Therapeutics takeout in $120-$140 range reasonable, says Cowen $78.70 / +16.62 (+26.77%)
12/12/22 William Blair Coupa Software downgraded to Market Perform from Outperform at William Blair 11/25/22 Raymond James Coupa Software takeout would be 'reasonable' at $68-$80, say Raymond James 11/25/22 Truist Truist sees 'scarcity value' in Coupa platform, keeps $75 target 11/25/22 BofA Coupa has strategic value, could also represent attractive PE target, says BofA 10/25/22 Wells Fargo Weber upgraded to Equal Weight from Underweight at Wells Fargo 08/17/22 Citi Weber downgraded to Sell from Neutral at Citi 08/16/22 BMO Capital Weber price target lowered to $6 from $7 at BMO Capital 08/02/22 Citi Weber transferred with Neutral rating at Citi 11/29/22 Evercore ISI Rivian Automotive initiated with an In Line, $35 target at Evercore ISI 11/29/22 Evercore ISI Rivian Automotive initiated with an In Line at Evercore ISI 11/10/22 RBC Capital Rivian Automotive price target lowered to $50 from $61 at RBC Capital 11/10/22 Deutsche Bank Rivian Automotive price target lowered to $43 from $44 at Deutsche Bank 11/18/22 Lake Street Inotiv downgraded to Hold from Buy at Lake Street 10/04/22 Jefferies Inotiv initiated with a Buy at Jefferies 08/11/22 Lake Street Inotiv price target raised to $60 from $50 at Lake Street 06/14/22 Lake Street Inotiv price target lowered to $50 from $75 at Lake Street 12/12/22 KeyBanc Coinbase initiated with a Sector Weight at KeyBanc 12/12/22 Mizuho Fiserv price target lowered to $135 from $145 at Mizuho 12/09/22 Mizuho Coinbase downgraded to Underperform from Neutral at Mizuho 12/05/22 Atlantic Equities Coinbase price target lowered to $46 from $67 at Atlantic Equities 11/25/22 William Blair Report about Galaxy S23 'significant positive' for Iridium, says William Blair 08/22/22 Loop Capital Enovix price target raised to $100 from $50 at Loop Capital 08/11/22 Loop Capital Loop Capital has 'stronger conviction' in Enovix after 'customer milestones' 06/22/22 Loop Capital Samsung initiated with a Buy at Loop Capital 12/09/22 BofA BofA upgrades Credit Suisse to Buy, sees more than 20% upside potential 12/09/22 BofA Credit Suisse upgraded to Buy from Neutral at BofA 12/01/22 JPMorgan Credit Suisse price target lowered to CHF 3.80 from CHF 5.50 at JPMorgan 11/07/22 AlphaValue/Baader Credit Suisse downgraded to Sell from Buy at AlphaValue/Baader 12/08/22 Citi DoD contracts shows competitiveness of cloud industry, says Citi 12/07/22 BTIG SentinelOne price target lowered to $20 from $25 at BTIG 12/01/22 BMO Capital Okta price target raised to $69 from $58 at BMO Capital 12/01/22 Wedbush Activision Blizzard added to Best Ideas List at Wedbush 12/06/22 Edward Jones Activision Blizzard upgraded to Buy from Hold at Edward Jones 11/28/22 JPMorgan Activision Blizzard price target lowered to $86 from $95 at JPMorgan 11/28/22 Wells Fargo Wells Fargo upgrades Activision Blizzard to Overweight with $95 price target 12/02/22 UBS IAC initiated with a Sell at UBS 11/14/22 Wells Fargo IAC price target lowered to $85 from $120 at Wells Fargo 11/10/22 Cowen IAC price target lowered to $75 from $80 at Cowen 11/10/22 Truist IACprice target lowered to $120 from $155 at Truist 07/08/22 H.C. Wainwright Meridian Bioscience downgraded to Neutral from Buy at H.C. Wainwright 07/07/22 William Blair Meridian Bioscience downgraded to Market Perform from Outperform at William Blair 02/07/22 H.C. Wainwright Meridian Bioscience price target raised to $30 from $28 at H.C. Wainwright 12/12/22 JPMorgan JPMorgan upgrades 'undervalued profitable growth story' Box to buy 12/12/22 JPMorgan Box upgraded to Overweight from Neutral at JPMorgan 11/21/22 Credit Suisse Box initiated with an Outperform at Credit Suisse 10/03/22 Morgan Stanley Morgan Stanley upgrades Box on 'strong large deal momentum' 12/12/22 H.C. Wainwright Adicet Bio price target raised to $38 from $34 at H.C. Wainwright 09/21/22 JPMorgan Adicet Bio initiated with Overweight, $23 target at JPMorgan 09/21/22 JPMorgan Adicet Bio initiated with an Overweight at JPMorgan 03/30/22 SMBC Nikko Adicet Bio initiated with an Outperform at SMBC Nikko 11/04/22 RBC Capital Karyopharm upgraded to Outperform from Sector Perform at RBC Capital 11/04/22 RBC Capital Karyopharm upgraded to Outperform from Sector Perform at RBC Capital 08/05/22 Baird Karyopharm price target lowered to $14 from $17 at Baird 08/05/22 Barclays Karyopharm price target lowered to $8 from $14 at Barclays 12/12/22 Oppenheimer Fate Therapeutics price target lowered to $65 from $90 at Oppenheimer 11/16/22 Citi Fate Therapeutics price target lowered to $80 from $87 at Citi 11/04/22 Cantor Fitzgerald Fate Therapeutics assumed with an Overweight at Cantor Fitzgerald 10/10/22 Canaccord Fate Therapeutics initiated with a Buy at Canaccord 09/13/22 H.C. Wainwright GT Biopharma price target lowered to $5 from $25 at H.C. Wainwright 08/11/22 Roth MKM Roth cuts GT Biopharma to Neutral after filings for TriKE programs pushed back 08/11/22 Roth MKM GT Biopharma downgraded to Neutral from Buy at Roth Capital 01/24/22 B. Riley GT Biopharma price target lowered to $18 from $26 at B. Riley 11/21/22 Cowen Whole Earth Brands price target lowered to $11 from $14 at Cowen 11/10/22 Canaccord Whole Earth Brands price target lowered to $8 from $10 at Canaccord 03/15/22 Lake Street Whole Earth Brands price target lowered to $16 from $19 at Lake Street 03/15/22 Cantor Fitzgerald Whole Earth Brands price target lowered to $19.00 from $24.75 at Cantor Fitzgerald 07/11/22 Rosenblatt Universal Technical initiated with a Buy at Rosenblatt 06/28/22 Argus Argus upgrades Universal Technical to Buy on expansion efforts, valuation 06/28/22 Argus Universal Technical upgraded to Buy from Hold at Argus 05/05/22 Barrington Universal Technical price target raised to $14 from $10 at Barrington 04/27/22 Jefferies Dynagas LNG reinstated with a Hold at Jefferies 12/09/22 Credit Suisse Pembina Pipeline downgraded to Neutral from Outperform at Credit Suisse 11/07/22 National Bank Pembina Pipeline price target raised to C$46 from C$45 at National Bank 11/04/22 Raymond James Pembina Pipeline price target lowered to C$46 from C$49 at Raymond James 10/20/22 Scotiabank Pembina Pipeline price target lowered to C$50 from C$55 at Scotiabank 12/12/22 Deutsche Bank Micron downgraded to Hold from Buy at Deutsche Bank 12/07/22 Wells Fargo Micron price target lowered to $70 from $75 at Wells Fargo 12/05/22 Lynx Micron price target raised to $60 from $56 at Lynx 11/30/22 Stifel Micron management's tone 'incrementally downbeat,' says Stifel $252.26 / -22.08 (-8.05%)
12/12/22 Cowen RH price target lowered to $320 from $350 at Cowen 12/12/22 Loop Capital RH price target lowered to $370 from $420 at Loop Capital 12/12/22 Barclays RH price target raised to $254 from $243 at Barclays 12/12/22 Goldman Sachs RH downgraded to Sell from Neutral at Goldman Sachs 12/12/22 Stifel Under Armour upgraded to Buy from Hold at Stifel 11/07/22 JPMorgan Under Armour price target raised to $11 from $10 at JPMorgan 11/01/22 BofA Under Armour reinstated with a Neutral at BofA 10/31/22 JPMorgan Under Armour price target lowered to $10 from $12 at JPMorgan 12/12/22 Wells Fargo Wells Fargo downgrades Qualcomm to Underweight with $105 price target 12/12/22 Wells Fargo Qualcomm downgraded to Underweight from Equal Weight at Wells Fargo 11/15/22 Credit Suisse Qualcomm initiated with an Outperform at Credit Suisse 11/03/22 KeyBanc Qualcomm price target lowered to $150 from $170 at KeyBanc 12/12/22 Piper Sandler Accenture downgraded to Underweight from Neutral at Piper Sandler 10/14/22 JPMorgan Accenture price target lowered to $306 from $329 at JPMorgan 10/13/22 Wells Fargo Wells sees some encouraging signs from emerging metaverse app economy 09/27/22 Alliance Global Partners Perficient upgraded to Buy from Neutral at Alliance Global Partners 12/12/22 Goldman Sachs Gap upgraded to Buy from Neutral at Goldman Sachs 11/21/22 Deutsche Bank Gap price target raised to $11 from $8 at Deutsche Bank 11/21/22 Barclays Gap price target raised to $14 from $9 at Barclays 11/18/22 Jefferies Gap price target raised to $13 from $11 at Jefferies 12/12/22 Goldman Sachs Tapestry upgraded to Buy from Neutral at Goldman Sachs 11/29/22 JPMorgan Tapestry price target raised to $47 from $46 at JPMorgan 11/14/22 Citi Tapestry price target lowered to $40 from $42 at Citi 11/11/22 Morgan Stanley Tapestry price target lowered to $35 from $39 at Morgan Stanley 12/12/22 Goldman Sachs Levi Strauss downgraded to Neutral from Buy at Goldman Sachs 11/29/22 JPMorgan Levi Strauss price target lowered to $19 from $20 at JPMorgan 10/10/22 Citi Levi Strauss price target lowered to $19 from $27 at Citi 10/07/22 Guggenheim Levi Strauss price target lowered to $27 from $33 at Guggenheim 08/15/22 Weber reports Q3 EPS (41c) 07/25/22 Weber withdraws FY22 guidance, suspends dividend 07/25/22 Weber sees Q3 revenue $525M-$530M, consensus $532.74M 11/22/22 Meridian Bioscience reports Q4 adjusted EPS 20c vs. 23c a year ago 08/05/22 Meridian Bioscience reports Q3 adjusted EPS 16c, consensus 16c 07/07/22 Meridian Bioscience sees Q3 revenue $66M-$69M 12/12/22 Virco reports Q3 EPS 48c vs. 8c last year 12/12/22 Universal Technical reports Q4 EPS 3c vs 20c last year 11/21/22 Universal Technical sees FY22 revenue $418.8M, consensus $418.98M 08/03/22 Universal Technical narrows FY22 revenue view to $410M-$420M from $405.0M-$420M 08/03/22 Universal Technical reports Q3 EPS (1c) vs. 3c a year ago 11/03/22 Under Armour cuts FY23 EPS view to 56c-60c from 61c-67c, consensus 43c 11/03/22 Under Armour reports Q2 adjusted EPS 20c, consensus 16c 11/02/22 Notable companies reporting before tomorrow's open 11/10/22 Tapestry sees FY23 EPS $3.60-$3.70, consensus $3.82 11/10/22 Tapestry reports Q1 EPS 79c, consensus 75c 11/09/22 Notable companies reporting before tomorrow's open 10/26/22 Samsung reports Q3 net profit KRW 9.39T vs. KRW 12.29T last year 10/06/22 Samsung sees Q3 operating profit KRW10.8T vs. KRW12.1T consensus 07/28/22 Samsung reports Q2 EPS KRW 1,613 vs. KRW 1,391 last year 07/06/22 Samsung sees Q2 operating profit KRW14.0T vs. KRW14.6T consensus 11/09/22 Rivian Automotive reports Q3 adjusted EPS ($1.57), consensus ($1.82) 11/09/22 Notable companies reporting after market close 10/27/22 Amazon reports Q3 EPS 28c with Rivian gain, consensus 21c 08/11/22 Rivian Automotive reports Q2 EPS ($1.89), consensus ($1.67) $252.26 / -22.08 (-8.05%)
12/08/22 RH narrow FY22 revenue growth view to down 4.5% to down 3.5% 12/08/22 RH reports Q3 EPS $5.67, consensus $4.70 12/08/22 Notable companies reporting after market close 09/08/22 RH sees Q3 revenue down 18% to down 15% 11/02/22 Qualcomm sees Q1 adjusted EPS adjusted EPS $2.25-$2.45, consensus $3.42 11/02/22 Qualcomm reports Q4 adjusted EPS $3.13, consensus $3.13 11/02/22 Notable companies reporting after market close 07/27/22 Qualcomm sees Q4 adjusted EPS $3.00-$3.30, consensus $3.23 12/12/22 Pembina Pipeline sees FY23 adjusted EBITDA C$3.5B-C$3.8B 11/03/22 Pembina Pipeline reports Q3 EPS C$3.23 vs. C$1.01 a year ago 08/04/22 Pembina Pipeline raises FY22 adjusted EBITDA view to C$3.575B-C$3.675B 08/04/22 Pembina Pipeline reports Q2 EPS C$0.69 vs. C$0.39 a year ago 12/12/22 Inotiv sees 2022 revenue $547.7M, consensus $550.98M 09/29/22 Micron sees Q2 revenue range similar to Q1 09/29/22 Micron sees Q1 adjusted EPS 4c, plus or minus 10c, consensus 64 09/29/22 Micron reports Q4 adjusted EPS $1.45, consensus $1.30 09/29/22 Notable companies reporting after market close 10/25/22 Microsoft sees FX decreasing total revenue growth by 5% in FY23 10/25/22 Microsoft reports Q1 EPS $2.35, consensus $2.30 10/25/22 Notable companies reporting after market close 07/26/22 Microsoft sees FY23 revenue growth in double digits, consensus $225.98B 10/06/22 Levi Strauss cuts FY22 EPS view to $1.44-$1.49 from $1.50-$1.56 10/06/22 Levi Strauss reports Q3 EPS 40c, consensus 37c 07/07/22 Levi Strauss backs FY22 adjusted EPS view $1.50-$1.56, consensus $1.55 07/07/22 Levi Strauss reports Q2 adjusted EPS 29c, consensus 23c 11/03/22 Karyopharm sees FY22 revenue $155M-$165M, consensus $157.23M 11/03/22 Karyopharm reports Q3 EPS (45) with items, consensus (57c) 08/04/22 Karyopharm sees 2022 revenue $155M-$165M, consensus $160.03M 08/04/22 Karyopharm reports Q2 EPS (62c), consensus (63c) 11/08/22 IAC reports Q3 EPS (74c), consensus (52c) 08/09/22 IAC reports Q2 EPS ($10.02), consensus (37c) HZNP Horizon Therapeutics $112.03 / +14.68 (+15.08%)
11/02/22 Horizon Therapeutics sees FY22 revenue s $3.59B-$3.61B, consensus $3.56B 11/02/22 Horizon Therapeutics reports Q3 EPS $1.25, consensus $1.01 08/03/22 Horizon Therapeutics cuts FY22 revenue view to $3.53B-$3.6B from $3.9B-$4B 08/03/22 Horizon Therapeutics reports Q2 adjusted EPS $1.07, consensus $1.35 11/17/22 Gap reports Q3 Gap brand revenue $1.04B, flat y/y 11/17/22 Gap sees Q4 revenue down mid-single digits, consensus $4.5B 11/17/22 Gap reports Q3 adjusted EPS 71c, consensus 0c 11/17/22 Notable companies reporting after market close 12/12/22 Whole Earth Brands reaffirms 2022 guidance 11/09/22 Whole Earth Brands sees 2022 revenue $535M-$545M, consensus $535.57M 11/09/22 Whole Earth Brands reports Q3 EPS (6c), consensus 8c 08/09/22 Whole Earth Brands reiterates FY22 revenue view $530M-$545M, consensus $536.83M 11/03/22 Fate Therapeutics reports Q3 EPS (86c), consensus (89c) 08/03/22 Fate Therapeutics reports Q2 EPS (79c), consensus (83c) 12/12/22 Dynagas LNG reports Q3 adjusted EPS 4c vs. 24c last year 09/22/22 Dynagas LNG reports Q2 EPS 17c vs. 20c in last year's quarter 10/27/22 Credit Suisse reports Q3 net revenue CHF 3.8B vs. CHF 5.43B last year 07/27/22 Credit Suisse reports Q2 net revenue CHF3.6B vs. CHF5.1B last year $78.70 / +16.62 (+26.77%)
12/12/22 Coupa Software reports Q3 non-GAAP EPS 15c, consensus 10c 09/06/22 Coupa Software sees FY23 non-GAAP EPS 37c-44c, consensus 26c 09/06/22 Coupa Software sees Q3 non-GAAP EPS 8c-10c, consensus 6c 09/06/22 Coupa Software reports Q2 non-GAAP EPS 20c, consensus 9c 12/07/22 Coinbase CEO tells Bloomberg 2022 revenue seen down 50% or more 11/03/22 Coinbase reports Q3 EPS ($2.43), consensus ($2.40) 08/09/22 Coinbase reports Q2 EPS ($4.98), consensus ($2.65) 11/30/22 Box raises FY23 EPS view to $1.16-$1.17 from $1.13-$1.16, consensus $1.14 11/30/22 Box sees Q4 adjusted EPS 34c-35c, consensus 33c 11/30/22 Box reports Q3 adjusted EPS 31c, consensus 30c 11/30/22 Notable companies reporting after market close 11/07/22 Activision Blizzard reports Q3 adjusted EPS 68c, consensus 50c 11/07/22 Notable companies reporting after market close 08/01/22 Activision Blizzard reports Q2 adjusted EPS 48c, consensus 48c 08/01/22 Notable companies reporting after market close $275.13 / -3.455 (-1.24%)
11/03/22 Amgen narrows FY22 adjusted EPS view to $17.25-$17.85 from $17.00-$18.00 11/03/22 Amgen reports Q3 adjusted EPS $4.70, consensus $4.44 11/03/22 Notable companies reporting after market close 08/04/22 Amgen backs FY22 adjusted EPS view $17.00-$18.00, consensus $17.40 09/22/22 Accenture sees Q1 revenue $15.2B-$15.75B, consensus $16.06B 09/22/22 Accenture sees FY23 EPS $11.09-$11.41, consensus $12.00 09/22/22 Accenture reports Q4 EPS $2.60, consensus $2.58 06/23/22 Accenture sees Q4 revenue $15B-$15.5B, consensus $14.83B 11/08/22 Adicet Bio reports Q3 EPS (53c), consensus (53c) 08/10/22 Adicet Bio reports Q2 EPS (56c), consensus (45c)
Recommendations
H.C. Wainwright analyst…
H.C. Wainwright analyst Edward White raised the firm's price target on Adicet Bio to $38 from $34 and keeps a Buy rating on the shares.
Show Hide Related Items >> <<
$17.27 / -2.585 (-13.02%)
12/11/22 Adicet Bio reports data from ongoing ADI-001 Phase 1 trial 11/29/22 Adicet Bio appoints Nancy Boman, M.D Chief Regulatory Officer 10/17/22 RA Capital Management reports 5.5% passive stake in Adicet Bio $17.27 / -2.585 (-13.02%)
09/21/22 JPMorgan Adicet Bio initiated with Overweight, $23 target at JPMorgan 09/21/22 JPMorgan Adicet Bio initiated with an Overweight at JPMorgan 03/30/22 SMBC Nikko Adicet Bio initiated with an Outperform at SMBC Nikko 03/17/22 JMP Securities Adicet Bio price target lowered to $21 from $30 at JMP Securities $17.27 / -2.585 (-13.02%)
11/08/22 Adicet Bio reports Q3 EPS (53c), consensus (53c) 08/10/22 Adicet Bio reports Q2 EPS (56c), consensus (45c)
Hot Stocks
Adicet Bio announced…
Adicet Bio announced safety and efficacy data from the company's ongoing Phase 1 study of ADI-001 for the potential treatment of relapsed or refractory B-cell NHL. The company believes these data continue to support the potential of Adicet's investigational gamma delta CAR T cell therapy to provide significant benefit both in terms of anti-tumor activity and safety. Based on the study findings as of a December 5, 2022 data-cut date, Adicet plans to transition ADI-001 into a potentially pivotal program in the second quarter of 2023. Of the 16 evaluable patients, three received ADI-001 at dose level 1, three received ADI-001 at DL2, three received ADI-001 at DL3, one received two infusions of ADI-001 at DL3, and six received ADI-001 at DL4. On an exploratory basis, primarily to understand safety and pharmacokinetics of a second ADI-001 dose, the first and second patient in DL3 while testing negative for minimal residual disease and in CR, received a second DL3 dose, three and two months after the first infusion, respectively. Patients were heavily pretreated with a median number of prior therapies of four and had a poor prognostic outlook based on their median International Prognostic Index score. ADI-001 treatment demonstrated a 75% ORR and 69% CR rate in the study across all dose levels. In five LBCL patients that previously relapsed after prior autologous anti-CD19 CAR T therapy, treatment with ADI-001 demonstrated 100% ORR and CR rate. These patients included a triple-hit high-grade B-cell lymphoma patient, three diffuse large B-cell lymphoma patients, and a double-hit high-grade B-cell lymphoma patient. ADI-001 resulted in CR in patients who previously showed a partial response to autologous CAR T. An 86% CR rate was observed in LBCL patients across DL3 and above. 75% CR rate in LBCL across all dose levels. Both DL2 and DL3 demonstrated a six-month CR rate of 33%; Patient follow up continues in DL4 to assess six-month durability. Circulating ADI-001 cells were visible through day 28 in peripheral blood at DL4. ADI-001 was generally well-tolerated in the study to date. There were no occurrences of dose-limiting toxicities, graft vs host disease, or Grade 3 or higher Cytokine Release Syndrome or immune effector cell-associated neurotoxicity syndrome reported. Enrollment in the Phase 1 clinical study of ADI-001 is currently ongoing to provide additional durability data and further support the recommended Phase 2 dose.
Show Hide Related Items >> <<
$17.27 / -2.585 (-13.02%)
11/29/22 Adicet Bio appoints Nancy Boman, M.D Chief Regulatory Officer 10/17/22 RA Capital Management reports 5.5% passive stake in Adicet Bio $17.27 / -2.585 (-13.02%)
09/21/22 JPMorgan Adicet Bio initiated with Overweight, $23 target at JPMorgan 09/21/22 JPMorgan Adicet Bio initiated with an Overweight at JPMorgan 03/30/22 SMBC Nikko Adicet Bio initiated with an Outperform at SMBC Nikko 03/17/22 JMP Securities Adicet Bio price target lowered to $21 from $30 at JMP Securities $17.27 / -2.585 (-13.02%)
11/08/22 Adicet Bio reports Q3 EPS (53c), consensus (53c) 08/10/22 Adicet Bio reports Q2 EPS (56c), consensus (45c)
Conference/Events
Emerging Biotechnology…
Emerging Biotechnology Analysts Breidenbach and Biegler, along with Drs. Rossi and Braunstein, discuss the evolving treatment landscapes in multiple myeloma and non-hodgkin lymphoma on an Analyst/Industry conference call to be held on December 1 at 11 am.
Show Hide Related Items >> <<
PSTX Poseida Therapeutics 10/05/22 Poseida Therapeutics to present trial in progress poster for Phase 1 study 08/11/22 Poseida Therapeutics expects cash to fund operations into at least mid-2024 06/29/22 Poseida Therapeutics' Gene Editing System shows efficacy in published study 11/07/22 Nkarta presents data on NK cell based combination therapies 07/25/22 Nkarta promotes Ralph Brandenberger to Chief Technical Officer 10/27/22 Mustang Bio announces Phase 1/2 trial data of MB-106 10/06/22 Mustang Bio treats first patient in Phase 1/2 trial of MB-106 07/27/22 Mustang Bio announces first patient treated by ex vivo lentiviral gene therapy 06/22/22 Mustang Bio announces FDA granted ODD to MB-106 11/21/22 FDA clears Legend Biotech's IND application for LB2102 to treat extensive NSLC 11/03/22 Legend Biotech announces seven studies accepted for presentation at ASH 06/05/22 Legend Biotech presents results from CARTITUDE clinical development program 06/03/22 Legend Biotech announces FDA clearance of LB1908 IND application 12/01/22 Cidara Therapeutics announces issuance of first U.S. patent for CD388 11/30/22 Johnson & Johnson names CEO Joaquin Duato as Chairman of the Board 11/30/22 AC Immune's ACI-35.030 selected for further development 11/29/22 Horizon Therapeutics jumps 33% after deal talks with Amgen, Janssen, Sanofi IPSC Century Therapeutics 11/11/22 Century Therapeutics presents preclinical data at SITC meeting 11/10/22 Century Therapeutics sees cash runway into 2025 10/03/22 Century Therapeutics appoints Daphne Quimi, Timothy Walbert to board 08/25/22 Century Therapeutics receives Study May Proceed notification for CNTY-101 10/17/22 Gracell doses first patients in Phase 2 trial of leukemia candidate GC007g 08/15/22 Gracell sees cash runway into 2024 08/01/22 Gracell names Dr. Wendy Li as Chief Medical Officer 07/19/22 Gracell names Dr. Samuel Zhang as Chief Business Officer 11/29/22 EC authorizes new low-dose of Gilead's Biktarvy to treat HIV in children 11/28/22 Gilead, Arcus provide update from fourth interim analysis of ARC-7 study 11/02/22 Jounce earns clinical milestone payment under agreement with Gilead 11/07/22 Fate announces exercise by ONO of option to FT825/ONO-8250 08/11/22 Cathie Wood's ARK Investment bought 628K shares of Fate Therapeutics today 08/09/22 Fate Therapeutics announces preclinical study results on iPSCs 06/30/22 Fate Therapeutics appoints Brian Powl Chief Commercial Officer DTIL Precision BioSciences 11/03/22 Precision BioSciences: Abstract on Azer-cel accepted for presentation at ASH 09/02/22 Precision BioSciences announces senior leadership organizational changes 06/27/22 Precision BioSciences announces closing of underwritten offering of stock 06/21/22 Precision BioSciences announces agreement with Novartis 10/27/22 Crispr announces COO Klein to step down to pursue external opportunities 09/28/22 Crispr Therapeutics announces FDA RMAT designation to CTX130 09/27/22 Vertex, Crispr announce regulatory submissions for exagamglogene autotemcel 06/21/22 Crispr Therapeutics down 11% as Virtual Innovation Day continues 11/29/22 Caribou Biosciences announces FDA granted RMAT, FTD to CB-010 11/21/22 Caribou Biosciences announces FDA clearance of IND application for CB-011 10/18/22 Caribou presents report on long-term follow up from patient dosed with CB-010 09/01/22 Caribou Biosciences follicular lymphoma treatment granted FDA orphan designation 11/10/22 Cellectis presents preclinical data on TALEN-edited Smart CAR T-cells 09/28/22 Cellectis appoints Mark Frattini as Chief Medical Officer 09/19/22 Zentalis appoints Carrie Brownstein as CMO 11/10/22 Celularity presents preclinical data on CYNK-101 at SITC 10/06/22 Celularity names John Haines as CAO, Brad Glover as COO 10/03/22 Celularity appoints Kilcoyne as Chief Medical Officer 09/26/22 Celularity publishes new data on placental-derived NK cells in IAV infections 11/29/22 Bristol-Myers, Envisagenics announce research collaboration 11/07/22 Supreme Court rejects Bristol-Myers appeal of patent ruling, Reuters reports 11/03/22 Kura Oncology enters financing transactions with Bristol-Myers Hercules Capital 10/31/22 Bristol-Myers' MDS candidate Reblozyl meets primary and secondary endpoints ALLO Allogene Therapeutics 11/29/22 Allogene unveils Dagger technology during R&D showcase 11/10/22 Allogene Therapeutics presents pre-clinical data on immune 'cloaking' 10/31/22 Allogene Overland Biopharm completes buildout of cGMP manufacturing facility 10/11/22 Allogene Therapeutics launches CART T Together 06/23/22 Beneficial owner of Arcellx New Enterprise Associates buys $5M in shares 06/21/22 Arcellx names Maryam Abdul-Kareem as General Counsel 06/03/22 Arcellx reports 'positive' clinical data from Phase 1 CART-ddBCMA study 11/29/22 Adicet Bio appoints Nancy Boman, M.D Chief Regulatory Officer 10/17/22 RA Capital Management reports 5.5% passive stake in Adicet Bio 06/06/22 Adicet Bio outlines data from ADI-001 study at ASCO meeting 09/21/22 JPMorgan Adicet Bio initiated with Overweight, $23 target at JPMorgan 09/21/22 JPMorgan Adicet Bio initiated with an Overweight at JPMorgan 03/30/22 SMBC Nikko Adicet Bio initiated with an Outperform at SMBC Nikko 03/17/22 JMP Securities Adicet Bio price target lowered to $21 from $30 at JMP Securities 10/31/22 Guggenheim Arcellx initiated with a Buy at Guggenheim 10/27/22 Needham Arcellx initiated with a Buy at Needham 07/20/22 Canaccord Canaccord starts Arcellx at Buy, sees 'best-in-class' potential 07/20/22 Canaccord Arcellx initiated with a Buy at Canaccord ALLO Allogene Therapeutics 11/21/22 H.C. Wainwright Allogene Therapeutics price target lowered to $29 from $43 at H.C. Wainwright 09/22/22 B. Riley Allogene Therapeutics price target lowered to $18 from $21 at B. Riley 09/20/22 B. Riley B. Riley replaces Allogene with Syndax as top pick for 2022 08/10/22 Raymond James Allogene Therapeutics downgraded to Market Perform from Outperform at Raymond James 11/17/22 Credit Suisse Bristol-Myers initiated with a Neutral at Credit Suisse 11/17/22 Morgan Stanley Ventyx Biosciences initiated with an Overweight at Morgan Stanley 11/14/22 BMO Capital CytomX Therapeutics downgraded to Market Perform from Outperform at BMO Capital 11/02/22 Evercore ISI Evercore starts Legend Biotech with an Outperform on Carvykti potential 08/25/22 Alliance Global Partners Celularity initiated with a Buy at Alliance Global Partners 08/23/22 Truist Celularity price target lowered to $6 from $10 at Truist 06/22/22 H.C. Wainwright Celularity initiated with a Buy at H.C. Wainwright 04/06/22 Truist Celularity downgraded to Hold from Buy at Truist 08/18/22 Citi Cellectis price target raised to $36 from $34 at Citi 05/18/22 Baird Cellectis upgraded to Outperform at Baird on valuation 'backstop' 05/18/22 Baird Cellectis upgraded to Outperform from Neutral at Baird 05/13/22 Barclays Cellectis price target lowered to $7 from $9 at Barclays 11/23/22 Citi Caribou Biosciences price target lowered to $37 from $38 at Citi 08/29/22 Citi Caribou Biosciences price target lowered to $38 from $39 at Citi 08/18/22 H.C. Wainwright Caribou Biosciences price target lowered to $27 from $28 at H.C. Wainwright 05/12/22 Citi Caribou Biosciences price target raised to $39 from $29 at Citi 11/23/22 Citi Crispr Therapeutics price target lowered to $63 from $83 at Citi 11/02/22 Barclays Crispr Therapeutics price target lowered to $61 from $88 at Barclays 11/02/22 Credit Suisse Crispr Therapeutics price target lowered to $78 from $90 at Credit Suisse 10/11/22 Morgan Stanley Crispr Therapeutics initiated with an Underweight at Morgan Stanley DTIL Precision BioSciences 11/10/22 H.C. Wainwright Precision BioSciences price target lowered to $17 from $20 at H.C. Wainwright 06/16/22 BMO Capital Precision BioSciences initiated with an Outperform at BMO Capital 06/09/22 William Blair Precision BioSciences downgraded to Market Perform at William Blair 12/13/21 BTIG Precision BioSciences price target raised to $20 from $16 at BTIG 11/16/22 Citi Fate Therapeutics price target lowered to $80 from $87 at Citi 11/04/22 Cantor Fitzgerald Fate Therapeutics assumed with an Overweight at Cantor Fitzgerald 10/10/22 Canaccord Fate Therapeutics initiated with a Buy at Canaccord 08/18/22 Wells Fargo Fate Therapeutics assumed with an Overweight at Wells Fargo 12/01/22 Oppenheimer Gilead price target raised to $105 from $95 at Oppenheimer 11/22/22 Guggenheim MacroGenics upgraded to Buy at Guggenheim ahead of near-term catalysts 11/09/22 Argus Gilead price target raised to $100 from $70 at Argus 11/08/22 Cowen Gilead price target raised to $90 from $80 at Cowen 09/22/22 Citi Gracell initiated with a Buy at Citi 08/18/22 Wells Fargo Gracell assumed with an Overweight at Wells Fargo 06/01/22 Cantor Fitzgerald Gracell initiated with an Overweight at Cantor Fitzgerald 05/27/22 Piper Sandler Gracell price target lowered to $10 from $25 at Piper Sandler IPSC Century Therapeutics 11/14/22 H.C. Wainwright Century Therapeutics price target lowered to $25 from $27 at H.C. Wainwright 11/11/22 Piper Sandler Century Therapeutics price target raised to $24 at Piper after R&D day 10/31/22 Guggenheim Century Therapeutics initiated with a Buy at Guggenheim 10/10/22 Canaccord Century Therapeutics initiated with a Buy at Canaccord 12/01/22 Jefferies Horizon Therapeutics price target raised to $125 from $101 at Jefferies 12/01/22 Morgan Stanley Johnson & Johnson price target raised to $178 from $170 at Morgan Stanley 11/30/22 Wells Fargo Horizon Therapeutics takeover value could be $135/share, says Wells Fargo 11/29/22 Craig-Hallum Craig-Hallum sees potential for competing Apollo Endosurgery bids 11/01/22 Evercore ISI Legend Biotech initiated with an Outperform at Evercore ISI 11/01/22 Cowen Cowen starts Legend Biotech with an Outperform on Carvykti potential 11/01/22 Cowen Legend Biotech initiated with an Outperform at Cowen 11/16/22 BTIG Mustang Bio price target lowered to $4 from $8 at BTIG 08/17/22 BTIG Bluebird's approval has positive read for Mustang Bio, says BTIG 07/14/22 B. Riley Mustang Bio price target lowered to $4 from $5 at B. Riley 05/23/22 B. Riley Mustang Bio price target lowered to $5 from $6 at B. Riley 11/16/22 Mizuho Nkarta price target lowered to $26 from $81 at Mizuho 11/10/22 Oppenheimer Nkarta price target lowered to $36 from $50 at Oppenheimer 10/10/22 Canaccord Nkarta initiated with a Buy at Canaccord 08/12/22 Cantor Fitzgerald Nkarta price target lowered to $38 from $60 at Cantor Fitzgerald PSTX Poseida Therapeutics 11/11/22 BTIG Poseida Therapeutics price target lowered to $14 from $20 at BTIG 08/09/22 Piper Sandler Poseida Therapeutics price target raised to $11 from $9 at Piper Sandler 05/13/22 BTIG Poseida Therapeutics price target lowered to $20 from $40 at BTIG 05/13/22 Piper Sandler Poseida Therapeutics price target lowered to $9 from $19 at Piper Sandler PSTX Poseida Therapeutics 11/10/22 Poseida Therapeutics reports Q3 EPS 92c, consensus (65c) 08/11/22 Poseida Therapeutics reports Q2 EPS (69c) vs (74c) last year 11/09/22 Nkarta reports Q3 EPS (58c), consensus (61c) 08/11/22 Nkarta reports Q2 EPS (61c), consensus (60c) 11/14/22 Mustang Bio reports Q3 EPS (18c), consensus (20c) 10/18/22 Johnson & Johnson cuts FY22 estimated reported sales view to $93.0B-$93.5B 10/18/22 Johnson & Johnson narrows FY22 adjusted operational EPS view to $10.70-$10.75 10/18/22 Johnson & Johnson narrows FY22 adjusted EPS view to $10.02-$10.07 10/18/22 Johnson & Johnson reports Q3 adjusted EPS $2.55, consensus $2.48 IPSC Century Therapeutics 11/10/22 Century Therapeutics reports Q3 EPS (53c), consensus (59c) 08/11/22 Century Therapeutics reports Q2 EPS (54c), consensus (52c) 11/14/22 Gracell reports Q3 EPS (7c), consensus (13c) 08/15/22 Gracell reports Q2 EPS (6c), consensus (7c) 10/27/22 Gilead raises FY22 adjusted EPS view to $6.95-$7.15 from $6.35-$6.75 10/27/22 Gilead Sciences reports Q3 adjusted EPS $1.90, consensus $1.43 10/27/22 Notable companies reporting after market close 08/02/22 Gilead raises FY22 adjusted EPS view $6.35-$6.75 from $6.20-$6.70 11/03/22 Fate Therapeutics reports Q3 EPS (86c), consensus (89c) 08/03/22 Fate Therapeutics reports Q2 EPS (79c), consensus (83c) DTIL Precision BioSciences 11/08/22 Precision BioSciences reports Q3 EPS (22c), consensus (26c) 08/08/22 Precision BioSciences reports Q2 EPS (46c), consensus (41c) 08/08/22 Crispr Therapeutics reports Q2 EPS ($2.40), consensus ($2.23) 11/08/22 Caribou Biosciences reports Q3 revenue $3.3M, consensus $3.7M 08/09/22 Caribou Biosciences reports Q2 EPS (44c), consensus (36c) 11/03/22 Cellectis reports Q3 EPS (63c), consensus (45c) 08/04/22 Cellectis reports Q2 EPS (88c), consensus (56c) 11/10/22 Celularity reports Q3 EPS 3c, consensus (26c) 08/09/22 Celularity reports Q2 EPS (32c), consensus (26c) 10/25/22 Notable companies reporting before tomorrow's open 10/25/22 Bristol-Myers affirms FY22 EPS view of $7.44 - $7.74, consensus $7.51 10/25/22 Bristol-Myers reports Q3 EPS $1.99, consensus $1.83 ALLO Allogene Therapeutics 08/09/22 Allogene Therapeutics reports Q2 EPS (52c), consensus (61c) 11/14/22 Arcellx reports Q3 EPS ($2.12), consensus (89c) 08/15/22 Arcellx reports Q2 EPS (88c), consensus ($1.07) 11/08/22 Adicet Bio reports Q3 EPS (53c), consensus (53c) 08/10/22 Adicet Bio reports Q2 EPS (56c), consensus (45c) 06/06/22 Notable companies reporting after market close
Conference/Events
Emerging Biotechnology…
Emerging Biotechnology Analysts Breidenbach and Biegler, along with Drs. Rossi and Braunstein, discuss the evolving treatment landscapes in multiple myeloma and non-hodgkin lymphoma on an Analyst/Industry conference call to be held on December 1 at 11 am.
Show Hide Related Items >> <<
PSTX Poseida Therapeutics 10/05/22 Poseida Therapeutics to present trial in progress poster for Phase 1 study 08/11/22 Poseida Therapeutics expects cash to fund operations into at least mid-2024 06/29/22 Poseida Therapeutics' Gene Editing System shows efficacy in published study 11/07/22 Nkarta presents data on NK cell based combination therapies 07/25/22 Nkarta promotes Ralph Brandenberger to Chief Technical Officer 10/27/22 Mustang Bio announces Phase 1/2 trial data of MB-106 10/06/22 Mustang Bio treats first patient in Phase 1/2 trial of MB-106 07/27/22 Mustang Bio announces first patient treated by ex vivo lentiviral gene therapy 06/22/22 Mustang Bio announces FDA granted ODD to MB-106 11/21/22 FDA clears Legend Biotech's IND application for LB2102 to treat extensive NSLC 11/03/22 Legend Biotech announces seven studies accepted for presentation at ASH 06/05/22 Legend Biotech presents results from CARTITUDE clinical development program 06/03/22 Legend Biotech announces FDA clearance of LB1908 IND application $177.94 / +1.895 (+1.08%)
11/30/22 Johnson & Johnson names CEO Joaquin Duato as Chairman of the Board 11/30/22 AC Immune's ACI-35.030 selected for further development 11/29/22 Horizon Therapeutics jumps 33% after deal talks with Amgen, Janssen, Sanofi 11/29/22 Horizon Therapeutics confirms preliminary deal talks with Amgen, Janssen, Sanofi IPSC Century Therapeutics 11/11/22 Century Therapeutics presents preclinical data at SITC meeting 11/10/22 Century Therapeutics sees cash runway into 2025 10/03/22 Century Therapeutics appoints Daphne Quimi, Timothy Walbert to board 08/25/22 Century Therapeutics receives Study May Proceed notification for CNTY-101 10/17/22 Gracell doses first patients in Phase 2 trial of leukemia candidate GC007g 08/15/22 Gracell sees cash runway into 2024 08/01/22 Gracell names Dr. Wendy Li as Chief Medical Officer 07/19/22 Gracell names Dr. Samuel Zhang as Chief Business Officer 11/29/22 EC authorizes new low-dose of Gilead's Biktarvy to treat HIV in children 11/28/22 Gilead, Arcus provide update from fourth interim analysis of ARC-7 study 11/02/22 Jounce earns clinical milestone payment under agreement with Gilead 11/07/22 Fate announces exercise by ONO of option to FT825/ONO-8250 08/11/22 Cathie Wood's ARK Investment bought 628K shares of Fate Therapeutics today 08/09/22 Fate Therapeutics announces preclinical study results on iPSCs 06/30/22 Fate Therapeutics appoints Brian Powl Chief Commercial Officer DTIL Precision BioSciences 11/03/22 Precision BioSciences: Abstract on Azer-cel accepted for presentation at ASH 09/02/22 Precision BioSciences announces senior leadership organizational changes 06/27/22 Precision BioSciences announces closing of underwritten offering of stock 06/21/22 Precision BioSciences announces agreement with Novartis 10/27/22 Crispr announces COO Klein to step down to pursue external opportunities 09/28/22 Crispr Therapeutics announces FDA RMAT designation to CTX130 09/27/22 Vertex, Crispr announce regulatory submissions for exagamglogene autotemcel 06/21/22 Crispr Therapeutics down 11% as Virtual Innovation Day continues 11/29/22 Caribou Biosciences announces FDA granted RMAT, FTD to CB-010 11/21/22 Caribou Biosciences announces FDA clearance of IND application for CB-011 10/18/22 Caribou presents report on long-term follow up from patient dosed with CB-010 09/01/22 Caribou Biosciences follicular lymphoma treatment granted FDA orphan designation 11/10/22 Cellectis presents preclinical data on TALEN-edited Smart CAR T-cells 09/28/22 Cellectis appoints Mark Frattini as Chief Medical Officer 09/19/22 Zentalis appoints Carrie Brownstein as CMO 11/10/22 Celularity presents preclinical data on CYNK-101 at SITC 10/06/22 Celularity names John Haines as CAO, Brad Glover as COO 10/03/22 Celularity appoints Kilcoyne as Chief Medical Officer 09/26/22 Celularity publishes new data on placental-derived NK cells in IAV infections 11/29/22 Bristol-Myers, Envisagenics announce research collaboration 11/07/22 Supreme Court rejects Bristol-Myers appeal of patent ruling, Reuters reports 11/03/22 Kura Oncology enters financing transactions with Bristol-Myers Hercules Capital 10/31/22 Bristol-Myers' MDS candidate Reblozyl meets primary and secondary endpoints ALLO Allogene Therapeutics 11/29/22 Allogene unveils Dagger technology during R&D showcase 11/10/22 Allogene Therapeutics presents pre-clinical data on immune 'cloaking' 10/31/22 Allogene Overland Biopharm completes buildout of cGMP manufacturing facility 10/11/22 Allogene Therapeutics launches CART T Together 06/23/22 Beneficial owner of Arcellx New Enterprise Associates buys $5M in shares 06/21/22 Arcellx names Maryam Abdul-Kareem as General Counsel 06/03/22 Arcellx reports 'positive' clinical data from Phase 1 CART-ddBCMA study 11/29/22 Adicet Bio appoints Nancy Boman, M.D Chief Regulatory Officer 10/17/22 RA Capital Management reports 5.5% passive stake in Adicet Bio 06/06/22 Adicet Bio outlines data from ADI-001 study at ASCO meeting 09/21/22 JPMorgan Adicet Bio initiated with Overweight, $23 target at JPMorgan 09/21/22 JPMorgan Adicet Bio initiated with an Overweight at JPMorgan 03/30/22 SMBC Nikko Adicet Bio initiated with an Outperform at SMBC Nikko 03/17/22 JMP Securities Adicet Bio price target lowered to $21 from $30 at JMP Securities 10/31/22 Guggenheim Arcellx initiated with a Buy at Guggenheim 10/27/22 Needham Arcellx initiated with a Buy at Needham 07/20/22 Canaccord Canaccord starts Arcellx at Buy, sees 'best-in-class' potential 07/20/22 Canaccord Arcellx initiated with a Buy at Canaccord ALLO Allogene Therapeutics 11/21/22 H.C. Wainwright Allogene Therapeutics price target lowered to $29 from $43 at H.C. Wainwright 09/22/22 B. Riley Allogene Therapeutics price target lowered to $18 from $21 at B. Riley 09/20/22 B. Riley B. Riley replaces Allogene with Syndax as top pick for 2022 08/10/22 Raymond James Allogene Therapeutics downgraded to Market Perform from Outperform at Raymond James 11/17/22 Credit Suisse Bristol-Myers initiated with a Neutral at Credit Suisse 11/17/22 Morgan Stanley Ventyx Biosciences initiated with an Overweight at Morgan Stanley 11/14/22 BMO Capital CytomX Therapeutics downgraded to Market Perform from Outperform at BMO Capital 11/02/22 Evercore ISI Evercore starts Legend Biotech with an Outperform on Carvykti potential 08/25/22 Alliance Global Partners Celularity initiated with a Buy at Alliance Global Partners 08/23/22 Truist Celularity price target lowered to $6 from $10 at Truist 06/22/22 H.C. Wainwright Celularity initiated with a Buy at H.C. Wainwright 04/06/22 Truist Celularity downgraded to Hold from Buy at Truist 08/18/22 Citi Cellectis price target raised to $36 from $34 at Citi 05/18/22 Baird Cellectis upgraded to Outperform at Baird on valuation 'backstop' 05/18/22 Baird Cellectis upgraded to Outperform from Neutral at Baird 05/13/22 Barclays Cellectis price target lowered to $7 from $9 at Barclays 11/23/22 Citi Caribou Biosciences price target lowered to $37 from $38 at Citi 08/29/22 Citi Caribou Biosciences price target lowered to $38 from $39 at Citi 08/18/22 H.C. Wainwright Caribou Biosciences price target lowered to $27 from $28 at H.C. Wainwright 05/12/22 Citi Caribou Biosciences price target raised to $39 from $29 at Citi 11/23/22 Citi Crispr Therapeutics price target lowered to $63 from $83 at Citi 11/02/22 Barclays Crispr Therapeutics price target lowered to $61 from $88 at Barclays 11/02/22 Credit Suisse Crispr Therapeutics price target lowered to $78 from $90 at Credit Suisse 10/11/22 Morgan Stanley Crispr Therapeutics initiated with an Underweight at Morgan Stanley DTIL Precision BioSciences 11/10/22 H.C. Wainwright Precision BioSciences price target lowered to $17 from $20 at H.C. Wainwright 06/16/22 BMO Capital Precision BioSciences initiated with an Outperform at BMO Capital 06/09/22 William Blair Precision BioSciences downgraded to Market Perform at William Blair 12/13/21 BTIG Precision BioSciences price target raised to $20 from $16 at BTIG 11/16/22 Citi Fate Therapeutics price target lowered to $80 from $87 at Citi 11/04/22 Cantor Fitzgerald Fate Therapeutics assumed with an Overweight at Cantor Fitzgerald 10/10/22 Canaccord Fate Therapeutics initiated with a Buy at Canaccord 08/18/22 Wells Fargo Fate Therapeutics assumed with an Overweight at Wells Fargo 11/22/22 Guggenheim MacroGenics upgraded to Buy at Guggenheim ahead of near-term catalysts 11/09/22 Argus Gilead price target raised to $100 from $70 at Argus 11/08/22 Cowen Gilead price target raised to $90 from $80 at Cowen 11/08/22 Mizuho Gilead price target raised to $88 from $75 at Mizuho 09/22/22 Citi Gracell initiated with a Buy at Citi 08/18/22 Wells Fargo Gracell assumed with an Overweight at Wells Fargo 06/01/22 Cantor Fitzgerald Gracell initiated with an Overweight at Cantor Fitzgerald 05/27/22 Piper Sandler Gracell price target lowered to $10 from $25 at Piper Sandler IPSC Century Therapeutics 11/14/22 H.C. Wainwright Century Therapeutics price target lowered to $25 from $27 at H.C. Wainwright 11/11/22 Piper Sandler Century Therapeutics price target raised to $24 at Piper after R&D day 10/31/22 Guggenheim Century Therapeutics initiated with a Buy at Guggenheim 10/10/22 Canaccord Century Therapeutics initiated with a Buy at Canaccord $177.94 / +1.895 (+1.08%)
11/30/22 Wells Fargo Horizon Therapeutics takeover value could be $135/share, says Wells Fargo 11/29/22 Craig-Hallum Craig-Hallum sees potential for competing Apollo Endosurgery bids 11/28/22 Morgan Stanley Genmab risk/reward favorable into arbitration ruling, says Morgan Stanley 11/17/22 Credit Suisse Johnson & Johnson initiated with a Neutral at Credit Suisse 11/01/22 Evercore ISI Legend Biotech initiated with an Outperform at Evercore ISI 11/01/22 Cowen Cowen starts Legend Biotech with an Outperform on Carvykti potential 11/01/22 Cowen Legend Biotech initiated with an Outperform at Cowen 11/16/22 BTIG Mustang Bio price target lowered to $4 from $8 at BTIG 08/17/22 BTIG Bluebird's approval has positive read for Mustang Bio, says BTIG 07/14/22 B. Riley Mustang Bio price target lowered to $4 from $5 at B. Riley 05/23/22 B. Riley Mustang Bio price target lowered to $5 from $6 at B. Riley 11/16/22 Mizuho Nkarta price target lowered to $26 from $81 at Mizuho 11/10/22 Oppenheimer Nkarta price target lowered to $36 from $50 at Oppenheimer 10/10/22 Canaccord Nkarta initiated with a Buy at Canaccord 08/12/22 Cantor Fitzgerald Nkarta price target lowered to $38 from $60 at Cantor Fitzgerald PSTX Poseida Therapeutics 11/11/22 BTIG Poseida Therapeutics price target lowered to $14 from $20 at BTIG 08/09/22 Piper Sandler Poseida Therapeutics price target raised to $11 from $9 at Piper Sandler 05/13/22 BTIG Poseida Therapeutics price target lowered to $20 from $40 at BTIG 05/13/22 Piper Sandler Poseida Therapeutics price target lowered to $9 from $19 at Piper Sandler PSTX Poseida Therapeutics 11/10/22 Poseida Therapeutics reports Q3 EPS 92c, consensus (65c) 08/11/22 Poseida Therapeutics reports Q2 EPS (69c) vs (74c) last year 11/09/22 Nkarta reports Q3 EPS (58c), consensus (61c) 08/11/22 Nkarta reports Q2 EPS (61c), consensus (60c) 11/14/22 Mustang Bio reports Q3 EPS (18c), consensus (20c) 06/01/22 Legend Biotech reports Q1 EPS (13c), consensus (46c) $177.94 / +1.895 (+1.08%)
10/18/22 Johnson & Johnson cuts FY22 estimated reported sales view to $93.0B-$93.5B 10/18/22 Johnson & Johnson narrows FY22 adjusted operational EPS view to $10.70-$10.75 10/18/22 Johnson & Johnson narrows FY22 adjusted EPS view to $10.02-$10.07 10/18/22 Johnson & Johnson reports Q3 adjusted EPS $2.55, consensus $2.48 IPSC Century Therapeutics 11/10/22 Century Therapeutics reports Q3 EPS (53c), consensus (59c) 08/11/22 Century Therapeutics reports Q2 EPS (54c), consensus (52c) 11/14/22 Gracell reports Q3 EPS (7c), consensus (13c) 08/15/22 Gracell reports Q2 EPS (6c), consensus (7c) 10/27/22 Gilead raises FY22 adjusted EPS view to $6.95-$7.15 from $6.35-$6.75 10/27/22 Gilead Sciences reports Q3 adjusted EPS $1.90, consensus $1.43 10/27/22 Notable companies reporting after market close 08/02/22 Gilead raises FY22 adjusted EPS view $6.35-$6.75 from $6.20-$6.70 11/03/22 Fate Therapeutics reports Q3 EPS (86c), consensus (89c) 08/03/22 Fate Therapeutics reports Q2 EPS (79c), consensus (83c) DTIL Precision BioSciences 11/08/22 Precision BioSciences reports Q3 EPS (22c), consensus (26c) 08/08/22 Precision BioSciences reports Q2 EPS (46c), consensus (41c) 08/08/22 Crispr Therapeutics reports Q2 EPS ($2.40), consensus ($2.23) 11/08/22 Caribou Biosciences reports Q3 revenue $3.3M, consensus $3.7M 08/09/22 Caribou Biosciences reports Q2 EPS (44c), consensus (36c) 11/03/22 Cellectis reports Q3 EPS (63c), consensus (45c) 08/04/22 Cellectis reports Q2 EPS (88c), consensus (56c) 11/10/22 Celularity reports Q3 EPS 3c, consensus (26c) 08/09/22 Celularity reports Q2 EPS (32c), consensus (26c) 10/25/22 Notable companies reporting before tomorrow's open 10/25/22 Bristol-Myers affirms FY22 EPS view of $7.44 - $7.74, consensus $7.51 10/25/22 Bristol-Myers reports Q3 EPS $1.99, consensus $1.83 ALLO Allogene Therapeutics 08/09/22 Allogene Therapeutics reports Q2 EPS (52c), consensus (61c) 11/14/22 Arcellx reports Q3 EPS ($2.12), consensus (89c) 08/15/22 Arcellx reports Q2 EPS (88c), consensus ($1.07) 11/08/22 Adicet Bio reports Q3 EPS (53c), consensus (53c) 08/10/22 Adicet Bio reports Q2 EPS (56c), consensus (45c) 06/06/22 Notable companies reporting after market close
Hot Stocks
Adicet Bio announced the…
Adicet Bio announced the appointment of Nancy Boman, M.D., Ph.D., as Senior Vice President and Chief Regulatory Officer. Dr. Boman will spearhead Adicet's regulatory strategy to further advance existing and new pipeline opportunities for the Company's gamma delta T cell platform. "We are incredibly excited to welcome Nancy to the Adicet team," said Chen Schor, President and Chief Executive Officer of Adicet Bio. "Her vast experience in successfully filing marketing applications for more than 15 products, including in hematologic malignancies, such as non-Hodgkin's lymphoma, is perfectly aligned with our plan to initiate a potentially pivotal program for ADI-001 in the first half of 2023. Nancy's leadership in building and expanding global regulatory operations particularly in the oncology field, including in solid tumors, is an asset to the team and positions us well as we expect to submit an IND application for ADI-925 in the second half of 2023 and potentially advance other pipeline programs, as disclosed in our recent R&D event, to regulatory submissions and clinical trials."
Show Hide Related Items >> <<
10/17/22 RA Capital Management reports 5.5% passive stake in Adicet Bio 06/06/22 Adicet Bio outlines data from ADI-001 study at ASCO meeting 09/21/22 JPMorgan Adicet Bio initiated with Overweight, $23 target at JPMorgan 09/21/22 JPMorgan Adicet Bio initiated with an Overweight at JPMorgan 03/30/22 SMBC Nikko Adicet Bio initiated with an Outperform at SMBC Nikko 03/17/22 JMP Securities Adicet Bio price target lowered to $21 from $30 at JMP Securities 11/08/22 Adicet Bio reports Q3 EPS (53c), consensus (53c) 08/10/22 Adicet Bio reports Q2 EPS (56c), consensus (45c) 06/06/22 Notable companies reporting after market close
Conference/Events
Emerging Biotechnology…
Emerging Biotechnology Analysts Breidenbach and Biegler, along with Drs. Rossi and Braunstein, discuss the evolving treatment landscapes in multiple myeloma and non-hodgkin lymphoma on an Analyst/Industry conference call to be held on December 1 at 11 am.
Show Hide Related Items >> <<
PSTX Poseida Therapeutics 10/05/22 Poseida Therapeutics to present trial in progress poster for Phase 1 study 08/11/22 Poseida Therapeutics expects cash to fund operations into at least mid-2024 06/29/22 Poseida Therapeutics' Gene Editing System shows efficacy in published study 05/31/22 Aadi Bioscience appoints Graham as SVP, IR, Corporates Communications 11/07/22 Nkarta presents data on NK cell based combination therapies 07/25/22 Nkarta promotes Ralph Brandenberger to Chief Technical Officer 10/27/22 Mustang Bio announces Phase 1/2 trial data of MB-106 10/06/22 Mustang Bio treats first patient in Phase 1/2 trial of MB-106 07/27/22 Mustang Bio announces first patient treated by ex vivo lentiviral gene therapy 06/22/22 Mustang Bio announces FDA granted ODD to MB-106 11/21/22 FDA clears Legend Biotech's IND application for LB2102 to treat extensive NSLC 11/03/22 Legend Biotech announces seven studies accepted for presentation at ASH 06/05/22 Legend Biotech presents results from CARTITUDE clinical development program 06/03/22 Legend Biotech announces FDA clearance of LB1908 IND application 11/22/22 BeiGene to present final PFS results from ALPINE trial at ASH 2022 11/17/22 Moderna appoints David Jimenez as general manager, U.S. 11/10/22 MeiraGTx announces $25M investment from Johnson & Johnson Innovation 11/07/22 Avalo sells economic rights to previously out-licensed assets for $5M IPSC Century Therapeutics 11/11/22 Century Therapeutics presents preclinical data at SITC meeting 11/10/22 Century Therapeutics sees cash runway into 2025 10/03/22 Century Therapeutics appoints Daphne Quimi, Timothy Walbert to board 08/25/22 Century Therapeutics receives Study May Proceed notification for CNTY-101 10/17/22 Gracell doses first patients in Phase 2 trial of leukemia candidate GC007g 08/15/22 Gracell sees cash runway into 2024 08/01/22 Gracell names Dr. Wendy Li as Chief Medical Officer 07/19/22 Gracell names Dr. Samuel Zhang as Chief Business Officer 11/28/22 Gilead, Arcus provide update from fourth interim analysis of ARC-7 study 11/02/22 Jounce earns clinical milestone payment under agreement with Gilead 11/02/22 FDA approves Gilead sNDA for Vemlidy to treat pediatric hepatitis B virus 11/07/22 Fate announces exercise by ONO of option to FT825/ONO-8250 08/11/22 Cathie Wood's ARK Investment bought 628K shares of Fate Therapeutics today 08/09/22 Fate Therapeutics announces preclinical study results on iPSCs 06/30/22 Fate Therapeutics appoints Brian Powl Chief Commercial Officer DTIL Precision BioSciences 11/03/22 Precision BioSciences: Abstract on Azer-cel accepted for presentation at ASH 09/02/22 Precision BioSciences announces senior leadership organizational changes 06/27/22 Precision BioSciences announces closing of underwritten offering of stock 06/21/22 Precision BioSciences announces agreement with Novartis 10/27/22 Crispr announces COO Klein to step down to pursue external opportunities 09/28/22 Crispr Therapeutics announces FDA RMAT designation to CTX130 09/27/22 Vertex, Crispr announce regulatory submissions for exagamglogene autotemcel 06/21/22 Crispr Therapeutics down 11% as Virtual Innovation Day continues 11/21/22 Caribou Biosciences announces FDA clearance of IND application for CB-011 10/18/22 Caribou presents report on long-term follow up from patient dosed with CB-010 09/01/22 Caribou Biosciences follicular lymphoma treatment granted FDA orphan designation 06/10/22 Caribou Biosciences presents data from ANTLER Phase 1 trial for CB-010 11/10/22 Cellectis presents preclinical data on TALEN-edited Smart CAR T-cells 09/28/22 Cellectis appoints Mark Frattini as Chief Medical Officer 09/19/22 Zentalis appoints Carrie Brownstein as CMO 11/10/22 Celularity presents preclinical data on CYNK-101 at SITC 10/06/22 Celularity names John Haines as CAO, Brad Glover as COO 10/03/22 Celularity appoints Kilcoyne as Chief Medical Officer 09/26/22 Celularity publishes new data on placental-derived NK cells in IAV infections 11/07/22 Supreme Court rejects Bristol-Myers appeal of patent ruling, Reuters reports 11/03/22 Kura Oncology enters financing transactions with Bristol-Myers Hercules Capital 10/31/22 Bristol-Myers' MDS candidate Reblozyl meets primary and secondary endpoints 10/27/22 Obsidian Therapeutics announces extension of agreement with Bristol-Myers ALLO Allogene Therapeutics 11/10/22 Allogene Therapeutics presents pre-clinical data on immune 'cloaking' 10/31/22 Allogene Overland Biopharm completes buildout of cGMP manufacturing facility 10/11/22 Allogene Therapeutics launches CART T Together 10/06/22 Allogene Therapeutics initiates ALLO-501A trial 06/23/22 Beneficial owner of Arcellx New Enterprise Associates buys $5M in shares 06/21/22 Arcellx names Maryam Abdul-Kareem as General Counsel 06/03/22 Arcellx reports 'positive' clinical data from Phase 1 CART-ddBCMA study 10/17/22 RA Capital Management reports 5.5% passive stake in Adicet Bio 06/06/22 Adicet Bio outlines data from ADI-001 study at ASCO meeting 09/21/22 JPMorgan Adicet Bio initiated with Overweight, $23 target at JPMorgan 09/21/22 JPMorgan Adicet Bio initiated with an Overweight at JPMorgan 03/30/22 SMBC Nikko Adicet Bio initiated with an Outperform at SMBC Nikko 03/17/22 JMP Securities Adicet Bio price target lowered to $21 from $30 at JMP Securities 10/31/22 Guggenheim Arcellx initiated with a Buy at Guggenheim 10/27/22 Needham Arcellx initiated with a Buy at Needham 07/20/22 Canaccord Canaccord starts Arcellx at Buy, sees 'best-in-class' potential 07/20/22 Canaccord Arcellx initiated with a Buy at Canaccord ALLO Allogene Therapeutics 11/21/22 H.C. Wainwright Allogene Therapeutics price target lowered to $29 from $43 at H.C. Wainwright 09/22/22 B. Riley Allogene Therapeutics price target lowered to $18 from $21 at B. Riley 09/20/22 B. Riley B. Riley replaces Allogene with Syndax as top pick for 2022 08/10/22 Raymond James Allogene Therapeutics downgraded to Market Perform from Outperform at Raymond James 11/17/22 Credit Suisse Bristol-Myers initiated with a Neutral at Credit Suisse 11/17/22 Morgan Stanley Ventyx Biosciences initiated with an Overweight at Morgan Stanley 11/14/22 BMO Capital CytomX Therapeutics downgraded to Market Perform from Outperform at BMO Capital 11/02/22 Evercore ISI Evercore starts Legend Biotech with an Outperform on Carvykti potential 08/25/22 Alliance Global Partners Celularity initiated with a Buy at Alliance Global Partners 08/23/22 Truist Celularity price target lowered to $6 from $10 at Truist 06/22/22 H.C. Wainwright Celularity initiated with a Buy at H.C. Wainwright 04/06/22 Truist Celularity downgraded to Hold from Buy at Truist 08/18/22 Citi Cellectis price target raised to $36 from $34 at Citi 05/18/22 Baird Cellectis upgraded to Outperform at Baird on valuation 'backstop' 05/18/22 Baird Cellectis upgraded to Outperform from Neutral at Baird 05/13/22 Barclays Cellectis price target lowered to $7 from $9 at Barclays 11/23/22 Citi Caribou Biosciences price target lowered to $37 from $38 at Citi 08/29/22 Citi Caribou Biosciences price target lowered to $38 from $39 at Citi 08/18/22 H.C. Wainwright Caribou Biosciences price target lowered to $27 from $28 at H.C. Wainwright 05/12/22 Citi Caribou Biosciences price target raised to $39 from $29 at Citi 11/23/22 Citi Crispr Therapeutics price target lowered to $63 from $83 at Citi 11/02/22 Barclays Crispr Therapeutics price target lowered to $61 from $88 at Barclays 11/02/22 Credit Suisse Crispr Therapeutics price target lowered to $78 from $90 at Credit Suisse 10/11/22 Morgan Stanley Crispr Therapeutics initiated with an Underweight at Morgan Stanley DTIL Precision BioSciences 11/10/22 H.C. Wainwright Precision BioSciences price target lowered to $17 from $20 at H.C. Wainwright 06/16/22 BMO Capital Precision BioSciences initiated with an Outperform at BMO Capital 06/09/22 William Blair Precision BioSciences downgraded to Market Perform at William Blair 12/13/21 BTIG Precision BioSciences price target raised to $20 from $16 at BTIG 11/16/22 Citi Fate Therapeutics price target lowered to $80 from $87 at Citi 11/04/22 Cantor Fitzgerald Fate Therapeutics assumed with an Overweight at Cantor Fitzgerald 10/10/22 Canaccord Fate Therapeutics initiated with a Buy at Canaccord 08/18/22 Wells Fargo Fate Therapeutics assumed with an Overweight at Wells Fargo 11/22/22 Guggenheim MacroGenics upgraded to Buy at Guggenheim ahead of near-term catalysts 11/09/22 Argus Gilead price target raised to $100 from $70 at Argus 11/08/22 Cowen Gilead price target raised to $90 from $80 at Cowen 11/08/22 Mizuho Gilead price target raised to $88 from $75 at Mizuho 09/22/22 Citi Gracell initiated with a Buy at Citi 08/18/22 Wells Fargo Gracell assumed with an Overweight at Wells Fargo 06/01/22 Cantor Fitzgerald Gracell initiated with an Overweight at Cantor Fitzgerald 05/27/22 Piper Sandler Gracell price target lowered to $10 from $25 at Piper Sandler IPSC Century Therapeutics 11/14/22 H.C. Wainwright Century Therapeutics price target lowered to $25 from $27 at H.C. Wainwright 11/11/22 Piper Sandler Century Therapeutics price target raised to $24 at Piper after R&D day 10/31/22 Guggenheim Century Therapeutics initiated with a Buy at Guggenheim 10/10/22 Canaccord Century Therapeutics initiated with a Buy at Canaccord 11/17/22 Credit Suisse Johnson & Johnson initiated with a Neutral at Credit Suisse 11/02/22 Morgan Stanley Abiomed upgraded to Equal Weight from Underweight at Morgan Stanley 11/02/22 Deutsche Bank Abiomed downgraded to Hold from Buy at Deutsche Bank 11/01/22 Piper Sandler Abiomed downgraded to Neutral from Overweight at Piper Sandler 11/01/22 Evercore ISI Legend Biotech initiated with an Outperform at Evercore ISI 11/01/22 Cowen Cowen starts Legend Biotech with an Outperform on Carvykti potential 11/01/22 Cowen Legend Biotech initiated with an Outperform at Cowen 11/16/22 BTIG Mustang Bio price target lowered to $4 from $8 at BTIG 08/17/22 BTIG Bluebird's approval has positive read for Mustang Bio, says BTIG 07/14/22 B. Riley Mustang Bio price target lowered to $4 from $5 at B. Riley 05/23/22 B. Riley Mustang Bio price target lowered to $5 from $6 at B. Riley 11/16/22 Mizuho Nkarta price target lowered to $26 from $81 at Mizuho 11/10/22 Oppenheimer Nkarta price target lowered to $36 from $50 at Oppenheimer 10/10/22 Canaccord Nkarta initiated with a Buy at Canaccord 08/12/22 Cantor Fitzgerald Nkarta price target lowered to $38 from $60 at Cantor Fitzgerald PSTX Poseida Therapeutics 11/11/22 BTIG Poseida Therapeutics price target lowered to $14 from $20 at BTIG 08/09/22 Piper Sandler Poseida Therapeutics price target raised to $11 from $9 at Piper Sandler 05/13/22 BTIG Poseida Therapeutics price target lowered to $20 from $40 at BTIG 05/13/22 Piper Sandler Poseida Therapeutics price target lowered to $9 from $19 at Piper Sandler PSTX Poseida Therapeutics 11/10/22 Poseida Therapeutics reports Q3 EPS 92c, consensus (65c) 08/11/22 Poseida Therapeutics reports Q2 EPS (69c) vs (74c) last year 11/09/22 Nkarta reports Q3 EPS (58c), consensus (61c) 08/11/22 Nkarta reports Q2 EPS (61c), consensus (60c) 11/14/22 Mustang Bio reports Q3 EPS (18c), consensus (20c) 06/01/22 Legend Biotech reports Q1 EPS (13c), consensus (46c) 10/18/22 Johnson & Johnson cuts FY22 estimated reported sales view to $93.0B-$93.5B 10/18/22 Johnson & Johnson narrows FY22 adjusted operational EPS view to $10.70-$10.75 10/18/22 Johnson & Johnson narrows FY22 adjusted EPS view to $10.02-$10.07 10/18/22 Johnson & Johnson reports Q3 adjusted EPS $2.55, consensus $2.48 IPSC Century Therapeutics 11/10/22 Century Therapeutics reports Q3 EPS (53c), consensus (59c) 08/11/22 Century Therapeutics reports Q2 EPS (54c), consensus (52c) 11/14/22 Gracell reports Q3 EPS (7c), consensus (13c) 08/15/22 Gracell reports Q2 EPS (6c), consensus (7c) 10/27/22 Gilead raises FY22 adjusted EPS view to $6.95-$7.15 from $6.35-$6.75 10/27/22 Gilead Sciences reports Q3 adjusted EPS $1.90, consensus $1.43 10/27/22 Notable companies reporting after market close 08/02/22 Gilead raises FY22 adjusted EPS view $6.35-$6.75 from $6.20-$6.70 11/03/22 Fate Therapeutics reports Q3 EPS (86c), consensus (89c) 08/03/22 Fate Therapeutics reports Q2 EPS (79c), consensus (83c) DTIL Precision BioSciences 11/08/22 Precision BioSciences reports Q3 EPS (22c), consensus (26c) 08/08/22 Precision BioSciences reports Q2 EPS (46c), consensus (41c) 08/08/22 Crispr Therapeutics reports Q2 EPS ($2.40), consensus ($2.23) 11/08/22 Caribou Biosciences reports Q3 revenue $3.3M, consensus $3.7M 08/09/22 Caribou Biosciences reports Q2 EPS (44c), consensus (36c) 11/03/22 Cellectis reports Q3 EPS (63c), consensus (45c) 08/04/22 Cellectis reports Q2 EPS (88c), consensus (56c) 11/10/22 Celularity reports Q3 EPS 3c, consensus (26c) 08/09/22 Celularity reports Q2 EPS (32c), consensus (26c) 10/25/22 Notable companies reporting before tomorrow's open 10/25/22 Bristol-Myers affirms FY22 EPS view of $7.44 - $7.74, consensus $7.51 10/25/22 Bristol-Myers reports Q3 EPS $1.99, consensus $1.83 ALLO Allogene Therapeutics 08/09/22 Allogene Therapeutics reports Q2 EPS (52c), consensus (61c) 11/14/22 Arcellx reports Q3 EPS ($2.12), consensus (89c) 08/15/22 Arcellx reports Q2 EPS (88c), consensus ($1.07) 11/08/22 Adicet Bio reports Q3 EPS (53c), consensus (53c) 08/10/22 Adicet Bio reports Q2 EPS (56c), consensus (45c) 06/06/22 Notable companies reporting after market close
Earnings
Cash and cash equivalents…
Cash and cash equivalents were $282.7 million as of September 30, 2022, compared to $277.5 million as of December 31, 2021. The Company expects that current cash and cash equivalents as of September 30, 2022, will be sufficient to fund its operating expenses into the first half of 2025. "We have continued to make very encouraging clinical progress in 2022, reporting promising safety and efficacy data for our lead candidate ADI-001 for the potential treatment of relapsed or refractory B-cell non-Hodgkin's lymphoma," said Chen Schor, CEO. "We're currently enrolling patients in dose level 4 and expect to initiate a potentially pivotal program with the recommended Phase 2 dose for ADI-001 in the first half of 2023. We look forward to providing additional clinical data on ADI-001 at the American Society of Hematology Annual Meeting in December as well as promising preclinical data on our emerging pipeline programs at the upcoming Society for Immunotherapy of Cancer's Annual Meeting and our upcoming R&D event."
Show Hide Related Items >> <<
10/17/22 RA Capital Management reports 5.5% passive stake in Adicet Bio 06/06/22 Adicet Bio outlines data from ADI-001 study at ASCO meeting 05/26/22 Adicet Bio's ADI-001 shows 67% response rate for NHL in Phase 1 trial 09/21/22 JPMorgan Adicet Bio initiated with Overweight, $23 target at JPMorgan 09/21/22 JPMorgan Adicet Bio initiated with an Overweight at JPMorgan 03/30/22 SMBC Nikko Adicet Bio initiated with an Outperform at SMBC Nikko 03/17/22 JMP Securities Adicet Bio price target lowered to $21 from $30 at JMP Securities 08/10/22 Adicet Bio reports Q2 EPS (56c), consensus (45c) 06/06/22 Notable companies reporting after market close 05/12/22 Adicet Bio reports Q1 EPS (12c), consensus (18c)
